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Chapter 1 
INTRODUeTION 
The origin of the studies, described in this thesis, dates back 
to 1979. In that year my colleague, R.P. Verhoeven, studied the 
responsiveness of hyperthyroid patients to beta adrenoceptor 
activation [1]. In his experiments he made the serendipitous 
observation that the plasma levels of the sympathetic 
transmitter, noradrenaline, increased during infusion of the beta 
adrenoceptor agonist isoprenaline. At the time most of us felt 
that this could be explained by reflex increase in sympathetic 
nervous activity, due to the vasodilatation caused by 
isoprenaline, my promotor, Prof. Schalekamp, took a different 
view. He suggested that the increase in noradrenaline during 
infusion of isoprenaline could be mediated by presynaptic beta 
adrenoceptors, which would serve to facilitate the release of 
noradrenaline [2,3,4]. He gave the impetus to the studies that 
followed. 
THE SYMPATHO-ADRENAL SYSTEM 
The autonomie nervous system consists of nerves cantrolling the 
functions of the heart, vascular and gut smooth muscle cells and 
several glands. Its efferent part can be divided in the cranio-
sacral outflow or parasympathetic nervous system and the thoraco-
lumbar outflow or sympathetic nervous system. The preganglionic 
sympathetic nerves run a short course from the cell bodies in the 
spinal cord to the ganglia in the sympathetic trunk, close to the 
vertebral column. Their neurotransmitter is acetylcholine. The 
postganglionic nerves run from the sympathetic trunk to the 
various effector organs. Their neurotransmitter is noradrenaline. 
Noradrenaline exerts its effects through receptors, which are 
designated 'alpha' or 'beta• adrenoceptors. Vasoconstriction is 
mediated by alpha receptors. The increase in heart rate and 
contractility and the stimulation of renin release are mediated 
by beta receptors. 
The medulla of the adrenal gland can be regarded as a 
homologue of the sympathetic ganglion. It is innervated by nerves 
that have acetylcholine as the neurotransmitter. When stimulated, 
the adrenomedullary cells liberate the hormone adrenaline, which 
differs from noradrenaline only by one additional methyl group ( 
Fig. 1). Adrenaline, like noradrenaline, exerts its effects on 
the target organs through alpha or beta adrenoceptors. Therefore, 
adrenaline and noradrenaline have many effects in common. 
Different affinities for a number of pharmacological compounds 
allowed these receptars to be further divided into the alpha-1, 
alpha-2, beta-l and beta-2 subtypes. Alpha-1, alpha-2 and beta-l 
receptars are activated both by adrenaline and noradrenaline. 
Beta-2 receptars are only activated by adrenaline. Beta-2 
receptor stimulation causes vasodilatation, bronchodilatation and 
a number of roetabolie effects. 
The sympathetic nervous system is tonically active, but its 
influence becomes greater with physical activity. Under resting 
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conditions circulating levels of adrenaline are very low, 
probably sub-threshold for most of its effects. Adrenaline rises 
to high levels under conditions of physical activity or "stress", 
like pain, shock, hypothermia, hypoglycemia, etc. Also mental 
stress raises adrenaline levels. [5]. 
Since the sympathetic nervous system and the adrenal medulla 
usually act in concert, and have many effects in common, the 
combination is aften referred to as the sympatho-adrenal system. 
The studies presented in this thesis are concerned with the 
possible influence of the adrenomedullary hormone, adrenaline, on 
the sympathetic nervous system. 
PRESYNAPTIC BETA ADRENOCEPTORS 
A sympathetic neuro-effector junction or synapse consists of (1) 
the sympathetic nerve ending or terminal varicosity which 
contains vesicles that store the transmitter noradrenaline, (2) 
the synaptic cleft, into which noradrenaline is released, and (3) 
the effector organ with its alpha andjor beta adrenoceptors, 
which, when activated by noradrenaline, cause that organ to 
respond ( see Fig. 2). The propagation of an electrical pulse 
into the nerve terminal leads to noradrenaline release. After its 
release, most noradrenaline is recaptured by the nerve ending 
into starage vesicles, from which it can be released again. Part 
of the noradrenaline is degraded in the surrounding tissue and a 
few percent leaks away and ultimately enters the blood [6]. 
The presence of several 'presynaptic' receptors, located on 
the nerve terminal itself, has been postulated. They are likely 
to exert a modulating influence on the amount of transmitter 
released in response to nerve stimulation. The best characterised 
are the presynaptic alpha adrenoceptors. It has been demonstrated 
that they can be activated by transmitter noradrenaline and 
mediate an inhibitory effect ( negative feedback) on further 
noradrenaline release [7]. 
In 1975 Adler-Graschinski and Langer, who studied 
noradrenaline release from isolated guinea pig atria, were the 
first to report an increased noradrenaline release in response to 
nerve stimulation in the presence of the beta adrenoceptor 
agonist isoprenaline [2]. since then, several beta agonists, 
including the hormone adrenaline, have been shown to facilitate 
the release of noradrenaline from a variety of tissues, 
irrespective of the type of postsynaptic receptor present. This 
facilitating effect has been shown to be reversible by beta 
antagonist drugs. Especially in blood vessels, presynaptic beta 
adrenergic facilitation of noradrenaline release has also been 
shown to augment the effector organ response. Thus, the existence 
of presynaptic beta adrenoceptors, which serve to facilitàte the 
release of noradrenaline in response to nerve stimulation, is 
weli established [for review see ref. 4]. 
Possible function of presynaptic beta adrenoceptors 
It was originally proposed that transmitter noradrenaline in low 
concentrations facilitates its own release through activatien of 
presynaptic beta receptors. At higher concentratien activatien of 
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presynaptic alpha receptars would lead to the opposite effect 
[2]. This view has now been abandoned. 
Based on the order of potency of different beta agonists on 
presynaptic receptors, the latter may be classified as being of 
the beta-2 subtype. Noradrenaline is nat a beta-2 agonist. Beta-2 
receptars are activated by adrenaline. In 1976 Stjärne and 
Brundin showed that adrenaline, in physiological concentrations, 
increased noradrenaline release from human omental arteries and 
veins in response to electrical stimulation. They were the first 
to suggest that presynaptic beta receptars serve to augment 
sympathetic transmitter release in situations of increased 
secretion of adrenaline [3]. In this way adrenaline would 
increase the 'gain' of the sympathetic nerveus system. 
In 1981 this hypothesis was somewhat modified by Majewski et 
al who showed that adrenaline, after intraveneus infusion, was 
taken up in rat atria and retained for several hours. After 
electrical stimulation of the isolated atria adrenaline was 'co-
released' tagether with noradrenaline. Thus, neuronal adrenaline 
could still act on presynaptic beta receptars at a time when 
blood levels are na langer elevated [8]. 
In vivo evidence of presynaptic beta adrenoceptors facilitating 
noradrenaline release 
At the time of Verhoeven's observation, that isoprenaline 
infusions in humans induce an increase in plasma noradrenaline, 
there was little in vivo evidence for a role of presynaptic beta 
adrenoceptors in noradrenaline release. In 1977 Yamaguchi et al, 
in experiments using electrical stimulation of the 
cardioaccelerator nerve in dogs, had shown that isoprenaline 
augmented the rise in coronary sinus plasma levels of 
noradrenaline. The betablocker sotalol had the opposite effect 
[9]. This evidence has recently been criticized because of the 
possible influence of altered noradrenaline kinetics resulting 
from changes in coronary blood flow [10]. In 1981 Dahl6f had 
shown that bath noradrenaline release from cat hindlimb mucle and 
vasoconstriction in response to lumbar nerve stimulation were 
reduced by beta adrenoceptor blockade [11]. In 1982 Majewski et 
al provided evidence for an increased noradrenaline release rate 
in rabbits after intraveneus administration of adrenaline, which 
could be prevented by a blocker of the neuronal uptake as well as 
by beta adrenoceptor blockade [12]. In vivo evidence for 
presynaptic beta adrenoceptors in man was entirely lacking when 
we started our studies on the effect of beta agonists on plasma 
noradrenaline concentratien ( see Chapters 2 and 3 ). 
Relevanee to physiology and pathophysiology 
Presynaptic facilitation of noradrenaline release by adrenaline 
will enhance alpha and beta-l receptor responses, for instanee 
vasoconstriction, increased cardiac output and renin release. One 
may wonder about the physiological significanee of this 
mechanism. In the classica! 'fright and flight' reaction 
adrenaline might prepare for an optimal response of cardiac 
output when muscular activity commences. It could further serve 
to counteract the fall in blood pressure that results from 
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vasodilitation in the active muscle groups. It is possible that 
under pathological conditions the implications of presynaptic 
effects of adrenaline are of greater importance than in normal 
circumstances. Majewski et al have shown that a slow release 
depot implantation containing adrenaline caused hypertension in 
rats. Since heart rate remained unchanged, the rise in blood 
pressure was likely to be due to a rise in peripheral vascular 
resistance. Blood pressure remained increased when blood levels 
of adrenaline had returned to normal. After pretreatment with a 
betablocker, adrenaline had no such effect [13]. Patients with 
essential hypertension aften have higher blood levels of 
adrenaline and noradrenaline than normotensive controls [14-17]. 
In such patients a positive correlation has been found between 
the level of adrenaline and the vasodilitation that could be 
achieved by alpha adrenoceptor blockade [18). These data suggest 
that adrenaline, presumably through presynaptic beta receptor 
activation, may increase vascular resistance and lead to 
hypertension. Indeed it is conceivable that increased secretion 
of adrenaline is the primary cause of essential hypertension 
[19]. 
Implications for betablocker therapy 
The mechanism by which betablockers lower blood pressur is 
unknown. Lowering of cardiac output, inhibition of renin 
production, resetting of the arterial barereflex and central 
nerveus system effects have all been put forward as the main 
mechanism underlying their antihypertensive effect. In 1976 
Stjärne and Brundin suggested the possibililty that betablockers 
exert their antihypertensive effect through blockade of 
presynaptic beta receptors. Their hypothesis was never widely 
accepted. There may be several reasans for this. First, evidence 
that presynaptic beta receptars are functionally active in man 
has long been lacking. Second, as presynaptic beta receptars are 
supposed to be of the beta-2 subtype, the hypothesis would 
predict that non-selective betablockers have a better 
antihypertensive effect than beta-l selective blockers. In fact, 
bath seem to be equally effective. Moreover, the antihypertensive 
potential of beta-2 selective blockade had not been studied. 
Third, one might expect presynaptic beta blockade to cause a fall 
in plasma noradrenaline, as is observed with clonidine, a 
centrally acting blocker of sympathetic nerveus activity. After 
betablockade, however, plasma noradrenaline is usually somewhat 
increased. This is difficult to reconcile with the view that 
betablockers inhibit noradrenaline release. 
AIMS OF THIS THESIS 
The main questions addressed in this thesis are: 
1} Can presynaptic beta-2 receptars be shown to be 
functionally active in intact man. 
2} What, if any, is their physiological role. 
3} Are these receptars involved in the antihypertensive 
effect of betablocker therapy. 
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our studies were performed in patiènts with untreated essential 
hypertension and in normotensive volunteers. First we studied the 
changes in plasma noradrenaline after administering beta receptor 
agonists and antagonists with different beta-l I beta-2 
selectivity. The effects on plasma noradrenaline were analysed in 
relation to several beta receptor mediated responses. Changes in 
heart rate, systolic time intervals and renin were taken as beta-
l receptor mediated responses. Changes in diastolic pressure and 
plasma potassium were taken as beta-2 mediated responses. This 
analysis allowed us to examine which beta receptor subtype was 
involved in the rise in noradrenaline and wether this rise was a 
direct effect of beta receptor activatien or the result of reflex 
sympathetic stimulation. 
Second, we studied the effects of adrenaline, infused in 
physiological doses, on plasma adrenaline and noradrenaline and 
on the cardiovascular responses to cold exposure and isometrie 
exercise. These studies were performed befere and after 
betablockade. 
Third, we carried out a double blind placebo controlled 
crossover trial in patients with essential hypertension to 
examine wether a selective beta-2 receptor antagonist is capable 
of lowering blood pressure. 
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ELEV ATED PLASMA NORADRENALINE IN RESPONSE TO 
{3-ADRENOCEPTOR STIMULA TION IN MAN 
H.H. VINCENT, A.J. MAN IN 't VELD, F. BOOMSMA 
G.J. WENTING & M.A.D.H. SCHALEKAMP 
Department of Internal MedicineL 
Erasmus University. Rotterdam. The Netherlands 
Oase-dependent increments of plasma noradrenaline were observed during graded infusions of 
(±)isoprenaline (3.5-35 ng kg-' min_, i.v.) inseven normal subjects and in ten subjects with 
borderline hypertension. At the highest dose ofisoprenaline, noradrenaline rose by 166 ± 16 pg/ml in 
normals and by 169 ± 34 pg/ml in hypertensives (mean ± s.e. mean). 
2 In the subjects with borderline hyperrension isoprenaline infusions were repeated after 7 days of 
treatment with (±)propranolol (320 mg/day, divided into 4 doses) and subsequently after 7 days of 
treatment with (±)atenolol (100 mg/day) 2-3 hafter the morning dose of )3-adrenoceptor blocker. 
The dose-response curve for plasma noradrenaline was shifted to higher doses of isoprenaline by a 
factor of 4 by atenolol and the heart rate response was similarly shifted. The heart rate response was 
shifted by a factor of 16 by propranolol, but plasma noradrenaline did notchange after isoprenaline 
under propranolol treatment. even when îsoprenaline was given at doses high enough to induce 
increments of he art ra te similar to those without ,8-adrenoceptor blocker treatment. 
3 In the subjects with borderline hypertension mean and diastolic intra-arterial pressures feil at the 
highest dose of isoprenaline by 9 ± 2 and 13 ± 2 mm Hg respectively. These effects were antagonized 
by propranolol and not by atenolol. 
4 The observed rise in plasma noradrenaline after isoprenaline might have been caused by baro-
reflex-stimulation of central sympathetic outflow. The isoprenaline-induced decreasein mean arterial 
pressure. however. was small. Moreover pulse pressure rose and this tencts to suppress rather than 
stimulate baroretlex-mediated sympathetic activity. Activation of presynaptic ,8-adrenoceptors. 
allegedly of the ,82 -subtype. is known to facilitate noradrenaline release upon nerve stimulation of 
isolated tissues. Our results lend support to the hypothesis that such a facilitatory mechanism is also 
operative in intact man. 
Introduetion 
Experimental studies have demonstrared that the 
release of noradrenaline from postganglionic sympa-
thetic nerve fibres can be modulated by a- and )3-
adrenoceptors. which are Iocated oil the nerve 
endings (Langer. 1977; Starke. 1977). Activation of 
these so-called presynaptic a-adrenoceptors by nor-
adrenaline triggers a negative feedback mechanism. 
by which the transmitter inhibits its own release. 
Measurements of noradrenaline overflow from iso-
lated tissues have shown that activation of presynap-
tic )3-adrcnoceptors has the opposite effect; through 
these receptars the release of the sympathetic trans-
mitter is facilitated during nerve stimulation (Langer. 
030&--5251/82/050717--<JS $01.00 
1977). Such a mechanism may contribute to the 
cardio-vascular actionsof ,B-adrenoceptor stimulants 
and blockers. lt mayalso be important in the physio-
logical control of sympathetic activity and in the 
pathogenesis ofhypertension. 
lt remains to be proved that )3-adrenoceptor-
mediated facilitation of noradrenaline release is 
operative in intact man. In the context of a study on 
the mechanism of )3-adrenoceptor blocker treatment 
of hyperrension we have given graded infusions of 
isoprenaline befare and after treatment with pro-
pranolol or atenolol and have measured the effects on 
plasma noradrenaline. The results are at least com-
© The Macmillan Press Ltd 1982 
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patible with the hypothesis that presynaptic {3-
adrenoceptors are important for the physiological 
reguiatien of noradrenaline release. 
Methods 
Seven normal subjects. aged 21-43 years (5 males) 
and ten subjects with hypertension. aged 21-40 years 
(all males) were studied. All subjects had given their 
informed consent. The hypertensive subjects were 
previously untreated, and blood pressure in the out-
patient clinic was 140-160 mm Hg systolic and 90-105 
mm Hg diastolic. They showed no signs of cardiac or 
renal disease and results of routine investigations. 
including intraveneus urography, were normaL 
The subjects were lying in bed. An indwelling 
cannula was placed in an arm vein fordrug infusion. 
A catheter was placed in the radial artery for pressure 
measurement and blood sampling. First, NaCI (0.15 
mol/I) was infused with a calibrated infusion pump at 
a rate of22 ml/h. After90min the infusion pump was 
~witched from saline to a salution of isoprenaline in 
saline. The dose was increased stepwise as indicated 
under Results. Each step lasled for 30 min. The total 
amount of fluid that was given was less than 100 mi. 
Arterial pressure and ECG were recorded con-
tinuously. The hypertensivc subjects were studiedon 
three occasions: (I) while untreated, (2) after 7 days 
on propranolol, 80 mg orally. 4 times daily, and (3) 
after 7 days on atenolol, 100 mg orally, once daily. 
The isoprenaline infusions were starled 2-3 h after 
the subjects had taken their morning dose of {3-
adrenoceptor blocker. 
· Blood samples for rneasurement of plasma nor-
adrenaline were drawn 30 and I min before starting 
isoprenaline infusion and at the end of each infusion 
step. Blood was collected in chilled heparinized 10 mi 
tubes containing 15 mg glutathione. Samples we re 
centrifuged within 15 min at 4"C. Under vigorous 
stirring 0.5 ml 3 M trichloroacetic acid was added 
to 4.5 mi plasma. The deproteinized plasma was 
separated by centrifugation at 4"C and stored at 
- 20"C. The samples were assayed within 2 weeks. 
Noradrenaline was measured by a radio-enzymatic 
method (Henry et al., 1975) in which noradrenaline is 
converted to tritiated adrenaline by ["H}-S-adenosyl--
r.-methionine and the enzyme phenylethanol-N-
methyltransferase. This method is highly specific for 
noradrenaline; adrenaline, dopamine and isoprena-
Hoe do not interfere. Measurements were made in 
duplicate both with and without actdition of nor-
adrenaline as intern al standard. Intra- and inter-assay 
variatien coefficients are less than 10%. All samples 
of one in fusion experiment were run in the same assay 
batch. 
Data arepresentedas means ± s.e. mean. 
Results 
Plasma noradrenaline was 219 ± 18 pg/ml in the 
normal subjects and it rose by !9 ± 7, 46 ± 11, 134 ± 
14 and 166 ± 16 pg/ml after isoprenaline at infusion 
rates of3.5, 7.0, !4and35 ng kg-• min-• respectively. 
It had returned to 249 ± 22 pg/ml 15 min after the 
in fusion of isoprenaline had been stopped. Five of the 
normal subjects had a control infusion of saline 
befere active drug was given. With saline alone 
plasma noradrenaline had changed by -6 ± 4 pg/ml 
at the last infusion step after 2 h, as compared with 
+ 159 ± 14 pg/ml after active drug. In the hyper-
tensive subjects the increase in noradrenaline was 
also dose-related and the response curve was similar 
to the curve in the normal subjects (Figure !). The 
effects of 7 days treatment with propranolol or ateno-
lol on resting levels of noradrenaline, heart rate and 
arterial pressure are presented in Table 1. Nor-
adrenaline had not significantly changed and the 
effects on heart rate and arterial pressure were not 
different for the two {3-adrenoceptor bloc kers. 
The dose-response curve for noradrenaline was 
shifted to higher doses of isoprenaline by a factor of 4 
by atenolol and the heart response was similarly 
shifted. The heart rate response was shifted by a 
factor of 16 by propranolol but plasma noradrenaline 
did not change after isoprenaline under propranolol 
320 
" ~ 240 
~ 
~=160 g{, 
.s:S ao 
" ~ 
.r:; 
u 
-80 
lsoprenaline infusion rate {ng kg-1 min_,) 
Figure 1 Changes in plasma noradrenaline and heart 
rate during isoprenaline infusion in ten subjects with 
borderline hypertension before ,B-adrenoceptor blocker 
treatment (a) and after treatment with atenolol (b) or 
propranolol (c). Thc means of the two pre-infusion 
values at -30 and -I min were taken as control values. 
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,B-ADREN9CEPTOR STIMULATION AND PLASMA NORADRENALINE 
Table 1 Basal values of plasma noradrenaline, heart rate and arterial pressure in the 
hypertensive subjects before and after ,8-adrenoceptor blocker treatment 
Arterial pressure 
Treatment Noradrenaline Heart rate systolic diastolic mean 
(pg/ml) (beats/min) (mmHg) (mmHg) (mmHg) 
None 224 ± 27 73 ± 3 152±4 77±3 99±4 
Ateno1o1 252::!: 28 54::!: 2 130±5 62 ± z 82:!: 3 100mgdai1y 
Propranolol 256 ± 24 52 ± 2 130 ± 5 66 ± 2 84±2 320mgdai1y 
Basal values in each subject are the means of the two values determined 30 and 1 min before 
isoprenaline in fusion was started. 
treatment, even when isoprenaline was given at doses 
high enough to induce increments of heart rate 
similar to those without ,8-adrenoceptor b!ocker 
treatment. 
Meao and diastolic intra-arterial pressure feil by 9 
± 2 and 13 ± 2 mm Hg respectively after isoprenaline, 
35 ng kg- 1 min -I, without ,8-adrenoceptor b!ocker 
treatment. Theyfellby 13 ± 3and21 ± 3mm Hgafter 
l 0~ ~I l:I!~ S~- - a c 
~ a.~-20 b 
~E~ . 
6~ --40 
~ ,~------~,0~,------~,0~,------~,03 
lsoprenaline infusion rate (ng kg_, min_,) 
Figure 2 Changes in arterial pulse pressure and in 
systolic. mean and diastolic arterial pressores during 
isoprenaline infusion in ten subjects with borderline 
hypertension before ,8-adrenoccptor blocker treatment 
(a) and after treatment with atenolol (b) orpropranolol 
( c). The means of the two pre-infusion values at -30 and 
-1 min were taken as control values. 
isoprenaline. 280 ng kg- 1 min- 1 with atenolol, and did 
notchange after isoprenaline, 560 ng kg- 1 min -I, with 
propranolol, despite similar increments of heart ra te, 
i.e. 51 ± 4 beats/min under atenolol and 48 ± 9 
beats/min under propranolol as compared with 44 ± 5 
beats/min without ,8-adrenoceptor blocker treat-
ment. 
Systolic intra-arterial pressure and pulse pressure 
rose with doses of isoprena!ine that increased heart 
ra te both befere ,8-adrenoceptor blocker treatment 
and during treatment with ateno!ol or propranoloL 
Discussion 
lt is generally accepted that short-term changes in 
plasma noradrenaline during various forms of physi-
cal stress are an index of sympathetic activity (Lake et 
al., !976; Watsonet al., 1979). Most likely. the dose-
dependent increments of noradrenaline we have 
observed during isoprenaline infusion arealso caused 
by increased release of the transmitter. 
One could argue that changes in the metabolic 
clearance rate of plasma noradrenaline have 
influenced our results. However, adrenaline and 
noradrenaline have been shown to accelerate their 
own clearance rate (Silverberg et al., 1978; Clutter et 
al .. 1980). wheréas propranolol is known to reduce 
the clearance of noradrenaline (Cryer et al., 1980). In 
view of these findings isoprenaline would be expected 
to accelerate the roetabolie clearance of noradrena-
line. This strengthens our condusion that the rise in 
plasma noradrenaline in response to isoprenaline 
infusion is caused by increased transmitter release 
and that this effect on transmitter release is bbcked 
by propranoloL 
Reflex stimulation of central sympathetic outflow 
through the carotico-aortic baroreceptor system 
might have caused the rise in noradrenaline we 
observed. However. there are reasans to assume that 
this is not the full explanation. Firstly, the fall in mean 
arterial pressure after isoprenaline was small and it is 
questionable whether the induced changes in baro-
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reflex activity were sufficient to be reflected by 
changes in plasma noradrenaline. lt has been 
reported that changes in transroural carotid sinus 
pressure elicited by means of a neck pressure 
chamber had no significant effect on plasma nor-
adrenaline, even when pressure increments in the 
neck chamber had led to opposite changes in mean 
arterial pressure in the range of W-15 mm Hg 
(Mancia et al .. 1979). Secondly. withdrawal of va gal 
tone through the baroreflcx would perhaps increa'>e 
the slope of the he art ra te close-response curve during 
isoprenaline infusion. The curve. however. was not 
steeper before J3-adrenoceptor blockcr treatment and 
with atenolol than with propranolol, whereas the 
hypotensive effect of isoprenaline was antagonized 
by propranolol and not by atcnolol. Thirdly. pulse 
pressure was increased by isoprenaline. This causes 
suppression rather than stimulation of barorctlex-
mediated sympathetic activity (Angell larnes & De 
Burgh Daly, 1970). 
Although a role for the bamreflex in the observed 
changes in plasma noradrenaline cannot be dis-
proved. our results are compatible with the hypo-
thesis that presynaptic J3-receptor-mediated facilita-
tion of noradrenaline release. which has been shown 
during ncrve stimulation of tissues in vitro (Langer. 
1Y77; Stjärne & Brundin. 1976), is also operalive in 
intact man. Such a facilitatory mechanism has also 
been demonstrated in vivo during cardioaccelerator 
ncrve stimulation in the anaesthetized dog (Yama-
guchieta/ .. 1977). 
In our study the non-selective ,B-adrcnoceptor 
blocker. propranolol. preventcd the effect of iso-
prenaline on noradrenaline even at doses of isoprcna-
line that caused tachycardia. whcreas the effect ofthe 
selective {31-adrenoceptor blocker. atenolol. on the 
noradrenaline response was overcome by such high 
doses of isoprenaline. This suggests that the facili-
tatory receptars are of the J3,-subtype. lt should be 
kcpt in mind however, that the J3 1-J3,-subdivision is 
based on the relative efficacies of {3-adrenoceptor 
drugs on postsynaptic receptors and not on presynap-
tic receptors. 
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Effects of Selective and Nonselective !3-Agonists on 
Plasma Potassium and Norepinephrine 
H. H. Vincent, F. Boomsma, A. J. Man in 't Veld, F. H. M. Derkx, G. J. Wenting, and 
M. A.D. H. Schalekamp 
Department of /nternal Medicine /, University Hospita/ Dijkzigt, Erasmus University, Rotterdam, The Netherlands 
Summary: The effects of graded infusions of the [3,-ago-
nists isoproterenol (nonselective). /-prenalterol ([3, 1-selec-
tive). and salbutamol ([3,2-selective) on plasma potassium 
and norepinephrine were compared in subjects with bor-
derline hypertension. Potassium levels feil with all three 
agonists. and norepinephrine levels rose with isoproter-
enol and salbutamol. These effects on potassium and nor-
epinephrine were closely correlated and occurred at the 
same dose ranges as the ·cardiovascular responses. The 
fall in plasma potassium was probably caused by activa-
tien of [3,-receptors, mainly on skeletal muscle. with sub-
sequent stimulation of active sodium-potassium transport 
across the cellolar membrane. The rise in plasma nor-
epinephrine may have been due to activation of [3,-recep-
tors on sympathetic nerve endings. Activatien of these 
presynaptic receptars is known to enhance the release of 
norepinephrine during nerve stimulation. For a given in-
crease in heart rate and cardiac contractility, as measured 
by the heart rate-corrected duration of total electrome-
chanical systole, which are mainly [3, 1-responses, the ef-
fects on potassium and norepinephrine were in the order: 
salbutamol > isoproterenol > prenalterol. [3,-Blockade 
There is grow.ing evidence that the sympathoad-
renal system is important for potassium homea-
stasis and that some drugs acting on adrenoceptors 
have a profound effect on the extracellular potas-
siurn concentration (1,2). Experiments with isolated 
tissues, skeletal muscle in particular, have demon-
strated that active sodium-potassium transport is 
stimulated when the tissue is exposed to epineph-
rine and 13-agonist drugs (3). Potassium is shifted by 
these agents to the intracellular compartment. The 
skeletal musdes contain the largest single pool of 
potassium in the body. and the rate of potassium 
exchange across the muscle plasma membrane is 
therefore of great importance for the minute-to-
minute regulation of the extracellolar potassium 
concentration. 
Received January 5, 1983; revision accepted August 10. 1983. 
Address correspondence and reprint requests to Dr. Schale-
with propranolol (nonselective). 80 mg four times a day, 
or atenatol ([3, 1-selective). 100 rng once a day, antagonized 
the hypokalemie effect of isoproterenol as welt as the rise 
in norepinephrine. but when isoproterenol was infused in 
doses high enough to overcome the blockade of the heart 
rate response. the effects on norepinephrine and potas-
siurn were abclisbed by propranolol and nat by atenolol. 
Thus. the receptars in question appear to be of the 132-
subtype. Epinephrine. which is known to circulate in high 
concentrations under stressfut conditions. is generally 
considered to be the endogenous activator of these re-
ceptors. 13-Blockers may prevent hypokalemia and may 
suppress sympathetic activity. which could contribute to 
their so-called cardioprotective action. The cvidence pre-
sented bere and in other studies that [3,2-type receptars 
are involved in stress-induced hypokalernia and in pre-
synaptic facilitation of norepinephrine release warrants 
further consideration of the clinical significanee of 13-
blocker selectivity. Key Words: [3, 1-Adrenoceptor-[3,2-
Adrenoceptor-Norepinephrine- Potassium- Presyn-
aptic 13-adrenoceptor. 
!t is also known that epinephrine and 13-agonist 
drugs act on sympathetic nerve endings to facilitate 
the release of norepinephrine (4-7). Recently, we 
observed a dose-dependent rise in plasma norepi-
nephrine during infusion of the nonselective 13-ag· 
onist isoproterenol in healthy volunteers and in sub· 
jects with borderline hypertension. Presynaptic fa-
ci!itation of transmitter release could be the 
underlying mechanism (8). 
Stimulation of norepinephrine release tagether 
with a decreasein extracellolar potas si urn may con-
tribute to the high incidence of cardiac arrhythmias 
in patients on 13-agonist drugs. High plasma levels 
of epinephrine and norepinephrine are known to 
occur in patients with myocardial infarction. In 
such cases epinephrine levels are high enough to 
kamp at Department of Intemal Medicine 1. Room P434. Dr. 
Malewaterplein 40. 3015 GD Rotterdam, The Netherlands. 
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induce hypokalemia (9). The nonsclective j3-blocker 
timolol prevents !he hypokalemie response to epi-
nephrine infusion (9). Propranolol, which is also a 
nonselective (3-blocker. diminishes the rise in 
plasma norepinephrine in patients with myocardial 
infarction (10). Prevention of j3-receptor-mediated 
hypokalemia and suppression of norepinephrine re-
lease may therefore contribute to the so-calied car-
dioprotective action of j3-blockers. 
In this context we have addressed the following 
questions. Does !he hypokalemie response to J3-ag-
onist drugs occur in the same dose range as their 
effect on plasma norepinephrine? How do these ef-
fects relate to the cardiovascular responses'! Which 
j3-receptor subtype is involved? 
METHOOS 
Patients 
Thirty male subjccts, aged 21-40 years. participated in 
the study after they had given their informed consent. 
They had borderline hypertension and were previously 
untreated. Blood pressure in the outpatient clinic was 
140-160 mm Hg systolic and 90-105 mm Hg diastolic. 
There were no signs of cardiac or renal disease. and re· 
sults of routine investigations, including intraveneus 
urogmphy, were normaL 
The ~·agonists isoproterenol sulfate (nonselective). f. 
prenalterol (H 133/22, Hässle~ [3 1·selective), and salbu-
tamol (Ventolin 00 , Glaxo; f3:--selectivc) were each given 
to 10 subjects. The subjects who received isoprotcreool 
were studied on three occasions, that is, befere [3-blocker 
tre-c~.tment. after 7 days of taking propranolol (lndeml 00 , 
ICI; nonselective 13-blocker) 80 mg tOur times a day, and 
finally after 7 days of taking atenolol (Tenorminau, ICI: 
13 1·selective blocker) 100 mg once daily. 
Infusions 
The subjects were lying in bed. A cannula was placed 
in an arm vein for drug infusions. A 20·gauge cannula 
(Quik-Cath. Travenoi) was placed in the mdial artery for 
pres~wre mcasurement and blood sampling. 
Isoproterenol and salbutamol wcre given via a cali· 
brd.ted infusion pump. First. 0.15 M NaCJ was infused at 
a rate of 22 ml/h. After I h the infusion was switched 
from saline to active drug. Concentratiens of active drug 
were chosen in such a way that the total quantity of tluid 
infused was Jess than 200 mi. The infusion rate of isopro-
terenol ranged from 3.5 to 35 ng kg· 1min- 1 in the absence 
of f>-blockade (n ~ 10), from 14 to 140 (n ~ 10) or 280 
(n = 4) ng kg- 1min 1 with atcnolol. and from 14 to 280 
(n = 10) or 560 (n = 5) ng kg 1min- 1 with propmnolol. 
The infusions in the subjects who were receiving 13-
blockers were started 2-3 hafter the morning dose of f3-
blocker. The infusion rate of i sopraterenol was increased 
stepwise, each step lasting 30 min. The infusion mte of 
salbutamol was increased from 17.5 to 175 ng kg- 1min 1 
in steps lasting 15 min. Because the half-life of the chro-
notropie effect of salbutamol is 20-60 min as opposed to 
about 5 min for isoprotere nol. a plateau state is not 
reached for salbutamol within 15 min. The maximum cu-
mulative dose was 4.5 tJ..g/kg. Blood samples were taken 
IS min befor.e starting active drug infusion, just beforc 
J Cftrdilll'(/,lt. Plwrmand. Vo{. ó, No. I, NN-I 
the infusion. and at the end of each infusion step. In five 
subjects who received isoproterenol and were not taking 
f3·blocker and in five subjects who received salbutamol, 
blood samples were also taken 15. 30, 45. and 60 min 
after the infusions had been stopped. 
Prenalterol was injected intravenously by hand. Each 
injection Jasted 5 min. and the interval between succes-
sive injections was 15 min. Doses were increased from I 
to 32 JJ.g/kg. As the half-life of the chronotropie effect of 
prenalterol is about 2 h, a plateau state is not reached in 
15 min. The maximum cumulative dose was 63 J.Lg/kg. 
Blood samples were taken 15 min before starting the in-
jections, just befare the injections. and 14-15 min after 
the start of each injection. 
Heart mte remained below 140 beats/min at maximum 
doses of 13-agonists. 
Measurements 
Intraarterial pressure and electrocardiographs (ECG) 
were continuously monitored. Systolic time intervals 
were recorded using the methad described by Lewis et 
al. ( 11 ). Changes in the duration of total electromechan· 
ical systole. measured as the time interval between the 
onset of the Q wave of the ECG and the initia! high· 
frequency vibrations of the aartic closure sound on the 
phonocardiogram eerreered for heart rate (QS21), were 
taken as an index of 13-adrenergic stimulation of cardiac 
contractility. Blood for norepinephrine measurement was 
collected in chilled, heparinized 10-ml tubes containing 
15 mg glutathione. The samples were centrifuged at 4°C 
within 15 min after collection. Under vigorous stirring, 
0.5 mi 3 M trichloroacetic acid was added to 4.5 mi 
plasma and the mixture was centrifuged. The deprotein-
ized supernatant was stared at - 20°C and assayed within 
2 weeks. A radioenzymatic methad was used in which 
norepinephrine is converted to tritiated epinephrine by 
phenylethanol-N-methyltransferase in the presence of 
[lHJS-adenosyl-/-methionine (8). Th is method is highly 
specific: the f3·agonists and blockers that were given to 
our subjects did not interfere. Measurements were made 
in duplicate both with and without actdition of norepi· 
nephrine as internal standard. Intra- and interassay vari-
ation coefficients were Jess than 10%. All samples from 
one infusion experiment were assayed in the same batch. 
Blood for potassium and sodium measurements Wds 
also collected in heparinized tubes and immediately cen-
trifuged. Plasma was stared at - 20oc until assayed in 
triplicate by flame Photometry. 
Statistics 
Results are reported as means ± SEM and were ana-
lyzed by Stuctent's t tests for paired and unpaired data. 
RESULTS 
Baseline measurements 
Data on blood pressure, heart rate. and plasma 
concentrdtions of norepinephrine and potassium be-
fore !3-agonists were given are summarized in Table 
f. There were no significant differences between 
the groups of subjects when untreated. 
Effects of j:l-agonists 
Figures 1-4 illustrate the effects of isoprot erenol, 
salbutamol, and prenalterol. All three agonists in-
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EFFECTS OF f3-AGONISTS ON POTASSlUM AND NOREPINEPHRINE 
T ABLE 1. Blood pre ss ure, heart rate, plasma norepinephrine, and plasma potassium in three groups of subjects 
befare f'>-agonist infusion 
Arterial pressure 
Systolic Mean 
Subjects (mmHg) (mmHg) 
Subjects to receive salbutamol 
(n = 10) without pretTeatment 136 ± 5 95 "4 
Subjects to receîve prenalterol 
(n = 10) without pretreatment 142 ± 4 95 ± 3 
Subjects to receive isoproterenol 
(n ~ 10) 
Without pretreatment 152 ± 4 99 ± 4 
With propranolol 130 ± 5 84" 2 
With atenolol 130 ± 5 82 ± 3 
creased heart rate and systolic pressure and short-
ened the total electromechanical systole (QS2l). 
Plasma norepinephrine rose with isoproterenol and 
salbutamol but was not significantly altered by 
prenalterol. whereas plasma potassium feil with all 
three drugs. There were no significant changes 
AR TERlAL ~ PRESSURE mmHg 
'" ~ 
HEART ]~l RATE bcat,./mln 
SYSTOUC 
'" TIME ~ INTkRVAL 
DOSE 
ng kg-lmln·t 
SALINE 
AG. 1. Cardiovascular effects of intraveneus isoproterenol 
(n = 10). Doses were 3.5, 7, 14, and 35 ng kg- 1min- 1. Sys-
tolic time interval refers to the duration of total electrome-
chanicaf systo-le corrected for haart rate (0821) and ex-
pressed in miUiseconds. 
20 
Heart Plasma Plasma 
Diastolic rate norepinephrine potassium 
(mmHg) (beats/min) (pg/ml) (mEq/L) 
74" 3 70" 3 226 ± 28 3.93 ± 0.06 
73 "2 64 ± 4 204" 21 3.81 ± 0.06 
77 " 3 73 ± 3 224 " 27 3.82 ± 0.09 
66" 2 52 ± 2 256 ± 24 3.83 ± 0.07 
62 ± 2 54 ± 2 252 ± 28 3.81 ± 0.08 
in plasma sodium. With isoproterenol 35 ng 
kg- 1min- 1• potassium feil below 3.40 mEq/L in 5 
of 10 subjects. Both potassium and norepinephrine 
returned to the initia! level 30-45 min after isopro-
terenol was stopped. With salbutamol. potassium 
became less than 3.40 mEq/L in 4 of 10 subjects 
ARTERtAL 
PRESSURE 
mmHg 
"' ~ 
~ 
HEART ~f~l RATE beahlmln 
SYSTOLtC 
TIME 
INTERVAL ~ 500 
'" OOSE ~ ng kg-lmln-1 SALINE 
15 JO 
mlm.nes 
RG. 2. Cardiovascular effects of intraveneus salbutamol (n 
= 10). Doses were 17.5, 35, 70, and 175 ng kg- 1min- 1• Sys-
tolic time interval rafers to the duration of total electrome-
chanical systole corrected for heart rate (052 1) and ex-
pressed in milliseconds. 
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AR TERlAL 
PRESSURE 
mmHg 
HEART 
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beatll/mln 
SYSTOLIC 
TIME 
INTERVAL 
DOSE 
~Jg/kg 
"' 
"' 
'" 
FIG. 3. Cardlovascular effects of Intraveneus prenalterol (n 
= 10). Doses ware i, 2, 4, 8, 16, and 32 ~J-9/kg. Systolic time 
interval rafers to the duration of total electromechanical sys· 
tole corrected tor haart rata (QS21) and expressed in milli-
seconds. 
after a cumulative dose of 4.5 fJ.g/kg. Both potas-
siurn and norepinephrine did not change for 30-45 
min after salbutamol was stopped. 
Fora given increment in heart rate and fora given 
shortening of the QS2I. the effects on norepineph-
rine and potassium were in the order: salbutamol > 
isoproterenol > prenalterol. 
Effects of ~-blockers 
Neither atenolol nor propranolol had a significant 
effect on the plasma concentrations of norepineph-
rine, potassium, and sodium. The rise of norepi-
nephrine and the decrease in potassium induced by 
isoproterenol were. however, antagonized by these 
13-blockers (Fig. 5). The heart rate response was 
shifted to the right by a dose factor of 5 with aten-
oio! and by a factor of !6 with propranolol. The 
shortening of QS2I, which is perhaps a more spe· 
cific 13 1-response, was shifted tothe right by a factor 
of 9 with both antagonists. When isoproterenol was 
given in quantities large enough to overcome the 
1 Cardio~·asc Pharmacol, Vol. 6, No. 1. 1984 
blockade of the heart rate response, the effects on 
norepinephrine and potassium were abo!ished by 
propranolol but not by atenolol. 
With isoproterenol140 ng kg- 1min- 1 under aten· 
olol, potassium feil below 3.40 mEqiL in 5 of 10 
subjects, and it was 1ess than 3.00 mEq!L in 2. In 
four subjects on atenolol, the rate of infusion of 
isoproterenol was increased to 280 ng kg- 1min- 1• 
Potassium fel! below 3.40 mEq/L in all four, and it 
was less than 3.00 mEq/L in two. 
DISCUSSION 
~1 versus ~2 effects 
This study confirms and extends reports that 13· 
receptor stimulation can induce hypokalemia. With 
isoproterenol, a short-acting 13-agonist drug, the 
half-life of the hypokalemie effect was 30 min or 
less. The change in potassium was too rapid to be 
explained by changes in urinary potassium excre-
tion. A rapid redistribution of potassium between 
the intracellular and extracellular compartments is 
the most likely explanation. Skeletal muscle is 
probably the main site of this potassium shift 
(12,13). 
Hypokalemie responses to the 13,-selective ago· 
nist salbutamol have been reported in the clinical 
Iiterature (14-19), but it is generally believed that 
such responses occur only at very high doses. How-
ever, the highest cumulative dose of 4.5 fJ.g/kg we 
have given is not above the range that is given to 
patients with an attack of asthma. A significant fall 
in plasma potassium occurred with doses that in-
creased heart rate by no more than 5 beats/min. 
With isoproterenol, which is a nonselective 13-ago-
nist, and with prenalterol, which is 131-selective, the 
hypokalemie effect was also seen over the same 
dose range as the chronotropie and inotropic re-
sponses, although for doses that were equipotent in 
raising heart rate or in shortening QS2I, the effect 
on potassium was Iess than that with salbutamol. 
The latter finding indicates that the decrease in 
plasma potassium is medialed by 132- rather than 131• 
receptors. This is further supported by our obser· 
vation that the nonselective 13-blocker propranolol, 
but not the 13 1-selective blocker atenolol, was able 
to antagonize the hypokalemie effect of isoproter-
enol. when the latter was given in doses high 
enough to overcome the blockade of the heart rate 
response. In experiments with isolated skeletal 
muscle, it is also the agents with 13,-agonist activity 
that promate active sodium-potassium transport; 
J3 1-selective agonists have little effect (20). 
The hypokalemie responses to salbutamol and 
isopro terenol were accompanied by a rise in plasma 
norepinephrine. There was a flxed ratio between 
the rise in norepinephrine and the fall in potassium; 
this ratio was the same for isoproterenol, both 
without pretreatment and after ateno1ol, as for sal· 
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FIG. 4. Effects of isoproterenol, salbu-
tamol, and prenalterol on the plasma con-
centratlens of norepinephrine and potas-
slum. The drugs were ad ministared as in-
dicated for Figs. 1-3. 
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butamol (Fig. 6). A similar correlation between the 
changes in norepinephrine and potassium was ob-
served with prenalterol (Fig. 6, left). The effects of 
isoproterenol on plasma potassium and norepineph-
. rine were equally blocked by propranolol (Fig. 6, 
right). This is an indication that the rise in norepi-
nephrine is also a fl2-receptor-mediated response. 
Theoretically, the rise in plasma norepinephrine 
may be caused by a diminished neuronal or extra-
neuronal upta.Ke of the transmitter. Isoproterenol 
bas little inhibitory effect on these uptake processes 
(21). Moreover, studies in man have shown that the 
clearance rate of plasma norepinephrine is in-
creased rather than decreased by fl-adrenoceptor 
stimulation (22). This strengthens the condusion 
that the rise in plasma norepinephrine we have ob-
served is caused by an increased release of the 
transmitter. 
Presynaptic versus postsynaptic effects 
fl-Agonists are known to facilitate norepinephrine 
release from sympathetic nerve endings through ac-
tivation of receptors located on them (4-6). This 
could be the mechanism by which plasma norepi-
nephrine is raised by isoproterenol and salbutamol. 
An alternative explanation could be that 13-receptor-
1 2 4 8 1& 32 
JJg/kg 
PRENAL TEROL 
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medialed vasodilatation activales the arterial bare-
reflex. The vascular recepters involved in this di-
latational effect are of the 13,-subtype, and there is 
evidence from in vitro experiments to suggest that 
the abovementioned presynaptic receptars are also 
ofthe l32-subtype (23-25). Our results are therefore 
in accord with both explanations insofar as j3,-
rather than 131-receptors seem to be involved in the 
changes in norepinephrine levels we have observed. 
Several lines of evidence argue against a domi-
nant role for the barereflex in the observed effects 
on norepinephrine. The decrease in mean arterial 
pressure in our experiments was small. Moreover. 
pulse pressure increased. which would suppress 
rather than stimulate baroreflex-mediated sympa-
thetic outflow (26). Sympathetic activity was re-
flexly increased by a neck pressure chamber by 
Mancia et al. (27). This caused a 20 mm Hg rise in 
mean arterial pressure. but plasma norepinephrine 
did not change. On the other hand, Grossman et al. 
(28) measured a 20 pg/ml rise in plasma norepi-
nephrine for every I mm Hg drop in mean arterial 
pressure during graded infusions of the vasodilator 
nitroprusside. Although we found a similar pres-
sure-norepinephrine relationship with isoproter-
enol, it should be emphasized that Grossman et al. 
J Cardiovasc Pharmacol, Vol. 6, No. 1, 1984 
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AG. 5. Antagonistic effects of ~blockers on isoproterenol-
induced changes in arterial pressure, heart rate, and plasma 
norepinephrineand potassium {n =: 10). Left: Dosa-response 
curve in the absence of ~blockade. Center: Oase-response 
curve ~lth atenolol pretreatment. Rlght: Dosa-response 
curve with propranolol pretreatment. 
(28) used an indirect metbod for measurlng arterlal 
pressure, whereas we measured it directly. More 
importantly, the blood pressure-norepinephrine rela-
tionship was quite different durlog salbutamol than 
durlog isoproterenol infusion. The drop in mean ar-
terlal pressure with low doses of salbutamol was 
not much different from that after high doses of 
isoproterenol. but norepinephrlne did not rise. In 
contrast, at higher doses of salbutamol, meao ar-
terlal pressure did not fall further, whereas norepi-
nephrlne rose to levels as high as or higher than 
those with isoproterenol. Perhaps the siroogest ar-
gument against the dominant influence of the arte-
rlal baroreflex on the observed changes in plasma 
norepinephrlne comes from the work of Arnold and 
MeDevilt (29). who found that the chronotropie ef-
fect of isoproterenol was not modified by pretreat · 
ment with atropine. As withdrawal of parasympa· 
thetic tone through the baroreflex is the main mech-
J Cardiovasc Pharmacol, Vol. 6, No. 1, 1984 
anism underlying tbe increase in heart rate after the 
administration of vasodilator drugs (30), these find-
ings cast doubt on an important contrlbution of the 
baroreflex. 
Pathophysiologic implications 
The pharmacologic evidence discussed indicates 
that ac:üvation of 13-receptors lowers plasma potas· 
sium and stimulates norepinephrlne release. The re· 
ceptors in question appear to be of the 132-subtype. 
Because the hormone epinephrine is a more potent 
stimulator of 13,-receptors than the neurotransmitter 
norepinephrine, it is likely that the endogenous cat · 
echolamine that produces these effects is epineph· 
rlne rathertban norepinephrlne. Epinephrlne in the 
extracellular fluid is taken up by sympathetic nerve 
endings. and following nerve stimulation, it is "'co· 
released" witb norepinephrine. It bas been proposed 
that coreleased epinephrlne may activate presyn-
aptic 13-receptors, thereby initiating a positive feed-
back loop by which the release of norepinephrlne 
is enhanced. In vitro experiments have indeed pro-
vided some evidence to support this proposal (6). 
High plasma levels of epinephrine have been doe-
urnenled in many forms of stress, including surgery, 
severe trauma, and myocardial infarction. It is in 
these conditions that transient bypokalemia can 
occur independently of gastrointestinal or renal po-
tassium losses (31-34). Epinephrine may therefore 
participate in stress·related hypokalemia. 
Conversely, an abnormal rise in plasma potas-
siurn bas been documented durlog physical exercise 
in healthy subjects who had been pretrealed with 
propranolol (35,36). Along the same lines, a rlse in 
plasma potassium bas been observed durlog surgery 
with cardiopulmonary bypass in patients who were 
receiving propranolol (37), whereas potassium usu-
ally falls in patients who are oot receiving 13· 
blockers (31). 
N ot only epinephrlne but also norepinephrlne is 
high in the abovementioned forms of stress. This 
reflects the increased sympathetic activity that is a 
characterlstic feature of these conditions. That pre-
synaptic facilitation of norepinephrlne release by 
epinephrine could play a role in such conditions is 
supported by the observation that propranolol re-
duces the increase in plasma norepinephrlne fol-
Iowing myocardial infarction (10). 
23 
Increased sympathetic drive to the heart logether 
with hypokalemia may predispose to cardiac ar-
rhythmias, particularly in patients with myocardial 
infarction. Both of these arrhythmogenic changes 
can be favorably influenced by 13-blockers, which 
may well contrlbute to the so-called cardioprotec-
tive effect of these drugs. This cardioprotective 
property appears to be shared by nonselective 13· 
blockers, as well as by 131-selective blockers (for 
review, see 38). Although at therapeutic doses the 
selectivity of these drugs máy be lost, the evidence 
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that 13r rather than 131-receptors are involved in 
stress-induced hypokalemia and presynaptic facili-
tation of sympathetic transmitter release warrants 
nuther consideration of the clinical significanee of 
13-blocker selectivity. 
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Chapter 4 
Stress Levels of Adrenaline Amplify the Blood Pressure 
Response to Sympathetic Stimulation* 
Hieronymus H. Vincent, Frans Boomsma, Arie J. Man in 't Veld 
and Maarten A.D.H. Schalekamp 
The possibility that sympathetic pressar responses are modulated by adrena!ine-
mediated facilitation of neuronal noradrenaline release was explored in 17 subjects with 
borderline hypertenslon. lnfusion of adrenaline, which raised plasma adrenaline by a 
factor of 8 to 9, augmented the rise in systolic and diastolic arterial pressure induced by 
standardized cold pressar and isometrie exercise tests. The heart rate response to 
these tests was nat affecteä When a low dose of propranolol was given on top of the 
adrenaline infusion befare the cold pressar test, the blood pressure response to cold 
exposure was nat different trom the response observed when the test was performed 
during saline infusion. Plasma noradrena!lne was higher during adrenaline infusion then 
during saline infusion, bath befare and after the cold pressar and isometrie exercise 
tests, and the effect of adrenaline on plasma noradrenaline was antagonized by 
propranoloL These observations are consistent with the hypothesis that stress levels of 
circulating adrenaline may amplify sympathetic pressar responses by facilitation of the 
release of transmitter noradrenaline. 
Journat of Hypertension 1986. 4:255·260 
Keywords: Adrenaline, noradrenaline, pre-synaptic ~-adrenoceptors, stress, 
hypertension. 
Introduetion 
In I'itro stuûi~s have shown that the release of 
norJ.drenaline from sympathetic nerves is enhanc~d by 
j3-adren<>Ceptor ag(>nist'> ! 1,2]. The receptt>rs involved 
appear to he of the J32·suhtype [3·S[, and are prohahly 
sensitive to th~ naturJ.lly occurrin~ 13-adrenoceptor 
agonist, adrenaline [ 2,S-H ]. These findings have· led to the 
hypothesis of modolation of n<...-'tlronal noradrenaline 
reie-J.se by adrenaline through activation of pre-synaptic 
~adrenoceptors loc..tred on sympathetic nerve endings. 
In this v.r..-ty adrenaline may indirectly increase 
sympathetic vasoconstricmr tone and therehy cause a rise 
in blood pressure [9]. 
In the present experiment" we studied the effect of 
adrenaline infusion on th~ blood pressure response to ~ 
reflex incre-J.se in sympathetic nervous activity. We also 
me-..tsured the dfe<...t of adrenaline on the pla~ma level of 
nt)radrenaline. 
From the Department of lnternal Medidne !, UniverSity Hospita! 
D1jkzigt, Erasmus University, Rotterdam. The Nether!ands. 
•Part of this work was presenled at the First European Meetmg on 
Hypertension, M1lan. ltaly, June 1983. 
Subjects 
Seventeen untreareû subject'> with borderline hyperten-
sion, aged lH-46 ye-..-trs, were studied. Their blood 
pre.ssure in the outparient clinic r.mged from 140 to 160 
mmHg systolic and 90 to 100 mmHg dia'>tolic. Routine 
inve:-,tigations, including urine- analyst ... , blood chemistry. 
elecrrocardiogrJ.m (ECG) and chest X-ray. revealed no 
sign" of cardiac or renal di.se-J.se. All subje<...1s gave their 
consent after a thorough explanation of the procedures 
and the purpose of the study; 
Methods 
The :-.tudies were perform~d while the suhject~ were 
supine and resting. }Je-Jn r..-tte wa." derived fn>m the ECG. 
Blood pressure W.I.'> measured directly through :.1 cannula 
in the radial artery. Drug infusions were given via a 
Requests tor reprints to: Or M.A.O.H. Scha!ekamp, Department of 
lnternal Medicine I, University Hospita! D1jkzigt. Dr Malewaterplein 
40. 3015 GD Rotterdam, The Nether!ands. 
Date of receiPI: 30 May 1985; revised: 27 September 1985 
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forearrn vein. 
All subjects performed a series of cold pressar tests by 
immersion of one hand up to the wrist in ice·water for 60 
s. Isometrie exercise tests were carried out in eight 
subjects by handgrip with one hand at 50% of maximal 
voluntarv contraction for 60 s. Heart rare, svstolic, 
diastolic. and integrated meao arterial pressuré were 
cominuously recorded .. An arterial blood sample was 
drawn within 30 s befare and 15 s after completion ofthe 
test. 
The blood samples were collected in chilled 10-ml 
tubes containing 12 mg of glutathione and 19 mg of 
ethyl ene-bis( oxyethylenenitrile )-tetraacetic acid (EGTA). 
The tubes were immediately centrifuged at 4°C. Part of 
the plasma (2.25 mi) was deproteinized with 3 mol/I 
trichloroacetic acid (0.25 mi), befere starage at -20°C. 
Assavs of adrenaline and noradrenaline were carried out 
in the deproteinized samples, within 2 weeks after blood 
collection. All samples of one subject were run in the 
same assay batch, in duplicate, both with and without 
internal standard. Adrenaline was determined by the 
radioenzymatle catechol-0-methyltransferase (COMT) 
methad as described by Peuler and Johnson [10]. This 
methad can also be used for determination of 
noradrenaline. However, in experimems with plasma 
enriched in adrenaline we have found that high levels of 
adrenaline occasionally interfere with the noradrenaline 
determination, resulting in erroneously elevated values 
for noradrenaline. To avoid this problem in the present 
investigations, where high levels of adrenaline occur, we 
determined noradrenaline separately by the selective 
radioenzymatic phenylethanolamine-N-methyltransferase 
(PNMT) methad described by Henry et al. [11]. Wlth this 
method the actdition of adrenaline up to 2000 pgiml ( 11 
nmoVl),in vitro did not interfere with the noradrenaline 
determination. 
Study protocol 
Saline was infused at a rate of 5.4 mlih for 30-45 mln 
befare baseline values were recorded. Two cold pressar 
tests were then performed 60 min apan, with three 
isometrie exercise tests at 15-min intervals in between. 
Subsequently, the infusion was switched to adrenaline, 
30 nglmin (0.16 fLmolimin) per kg body weight in an 
equal volume of saline. This was not notleed by the 
subjects. After 30 min the tests were repeated in the same 
sequence as before. In seven subjects propranolol, 0.5 
mg i.v, was injected while the infusion of adrenaline was 
continued. After 20 min two more cold presser tests were 
performed, now 20 min apart. To examine the possibility 
of an order effect the following two experiments were 
performed. First, the adrenaline infusion was continued 
in four subjects for a toral of 120 min without adding 
propranolol, and an additional cold pressar test was 
performed at the end of this period. Second, a cold 
pressar test 'WaS performed in five subjects 30 min after 
changing back from adrenaline to saline infusion. 
Statistical analysis 
Results of the two cold pressar tests during adrenaline 
infusion were averaged and compared with the average 
of the two tests during saline infusion and with the 
average of the rwo tests during adrenaline plus 
propranolol. Results of the isometrie exercise tests were 
analysed in a similar way. Data are presenred a"i means ± 
s.e.m. 
Differences between responses during infusion of 
saline, adrenaline and adrenaline plus propranolol were 
compared by three-way analysis of variance, with type of 
treatmeflt, subjects and time after beginning of the test 
considered as sourees of variation. For this analvsis the 
varianee due to rreatment was compared with tha{ due to 
the interaction between treatment and subjects. This 
analysis showed significant effects of treatment, but there 
was also a significant interaction between treatmem and 
time (P < 0.001 for ::he blood pressure response to cold 
exposure). We therefore subsequently evaluated the 
effects of treatmem at each time point by Studem's t-rest 
for paired observations. The latter test was also used to 
cernpare the dUferences in plasma catecholamine levels. 
A P value < 0.05 was considered to be significant. 
Results 
Effects of adrenaline infusion 
Adrenaline, 30 nglmin (0.16 fLmOI!min) per kg body 
weight, caused an eight- to ninefold rise in plasma 
adrenaline. This was sufficiem to exen a detectable 
cardiovascular effect. There was also a significant rise in 
plasma noradrenaline (Table 1). 
Table 1. Effects of adrenaline during sup'1ne rest (n = 17) 
Saline Adrenaline 
30 min 30 min p 
Arte(!al pressure (mmHg) 
Systolic 148 ± 2 148 ± 3 NS 
Mean 101 ±2 91 ± 1 <0.001 
Diastolic 80 ± 1 69 ± 1 <0.001 
Heart rate (beats/min) 73 ± 2 82 ± 2 <0.001 
Adrenaline (nmoJ/1) 0.47 ± 0.07 4.17 ± 0.55 <0.001 
Noradrenaline (nmol/J) 1.29±0.17 1.56 ± 0.21 <0.05 
NS, not significant. 
With the colcl. presser test during control saline 
infusion there was a gradual rise in both systolic and 
diastolic ancrial pressure over the 60-s periad. Hean rate 
rose more abruptly within 10 s. The pressar effect of col ct 
e>.:pasure was increased by adrenaline infusion. The 
increments of systolie and diastolic anerial pressure in 
the 20-60-s period were significantly greater than during 
saline infusion. The rise in heart rate was not altered by 
adrenaline (Fig. 1). Thirty minmes after the adrenaline 
infusion was switched back to saline the pressar 
response to cald exposure did not d.iffer from the 
response during the first saline period. Thus, it seems 
unlikely that the increased pressar response observed 
during adrenaline was due to an order effect. 
Isometrie exercise also caused a gradual rise in both 
systolic and diastolic arrerial pressure, and a more abrupt 
rise in heart rare. Adrenaline infusion had an effect on the 
pressar response to isometrie exercise simHar to the 
effect observed with the cold pressar test, and again the 
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Fig. 1. Cold pressar test, during infuslon of saline (0), adrenaline 
(•) and adrenaline atter administration at propranolol (l!.). • P < 
oos.··p < o.o1.···p < o.oo1. 
hean rare response was not altered (Fig. 2). 
In both tests plasma noradrenaline rose significantly 
during adrenaline infusion but not during control saline 
infusion (Fig. 3 ). The levels of noradrenaline that we re 
reached after the tests were higher dming adrenaline 
infusion than during saline infusion. The tests had no 
significant effect on plasma adrenaline. 
Effects of propranolol injection 
The effects of adrenaline on arrerial pressure and heart 
rate were fully amagonized by propranolol, 0.5 mg i.v, 
and blood pressure and heart rate after adrenaline plus 
propranolol and with the control saline infusion were 
nor difftrent. The blood pressure and heart rate 
responses to cold e:-..-posure after adrenaline plus 
propranolol were also oot different from the responses 
during saline infusion (Fig. 1). After infusion of 
adrenaline for 120 min, without adding propranolol, the 
pressar response to cold exposure was enhanced to the 
same extent as it vvas after 30 and 90 min of infusion. It is 
therefore unlikely that the diminished pressor response 
ro cold exposure during adrenaline plus propranolol, 
compared 'With adrenaline alone, was due to an order 
effect. 
With adrenaline plus propranolol, plasma adrenaline 
was higher then with adrenaline alone (Table 2). In 
comrao;t, plasma noradrenaline was lower v..'ith 
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CHANGE IN 40 
SYSTOLIC 
AR TERlAL 
PRESSURE 30 
mmHg 
20 
10 
CHANCE IN 40 
MEAN 
AR TERlAL 
PRESSURE 30 
mmHg 
20 
10 
CHANGE IN 30 
DIASTOLJC 
ARTERIAL 
PRESSURE 20 
mmHg 
10 
CHANGE IN 40 
HEART 
RATE 
bpm 
20 
. 
~ 
~ 
~ 
n=S 
20 40 60 
TIME 
Fig. 2. Isometrie handgrip exercise, during infusion of saline (0) 
and adrenaline (0). ··p < 0.05, **1P < 0.01 
adrenaline plus propranolol than with adrenaline alone, 
both before and after the cold pressor test (Fig. 4). 
Discussion 
Pressor responses 
The present study ·was aimed at the possible role of 
adrenaline-mediated modulation of noradrenaline 
release in cardiovascular homeostasis. We therefore 
infused adrenaline at such a rate that its plasma level 
remained within the physiological range. This range is 
from less than 0.25 nmol!l at rest to about 5·7.5 nmoVl 
during heavy exercise [ 12 ]. During infusion of adrenaline 
a plasma level ranging from 1. 5 to 6.5 nmoVl was reached 
in our subjects. 
The cold pres.•;or test evokes a sympathei:ic reflex, 
which leads to vasoconstriction and a rise in blood 
pressure, and this is prevented by a-adrenoceptor 
blockade [13,14]. Beta·adrenoceptor blockade does not 
28 
Chapter 4 
Journal of Hypertension 1986, Vol 4 No 2 
Table 2. Effects of adrenaline alone and adrenaline plus propranolol dunng supine rest (n = 7). 
Arterial pressure (mmHg) 
Systolic 
Mean 
Dlastolic 
Saline 
30 min 
Adrenaline 
30 min 
157 3 
94 
72 
Adrenaline 
plus propranolol 
20 min p• 
154 NS 
102 <0.001 
82 <0.001 
Heart rate {beats/min) 
Adrenaline (nmal/1) 
Noradrenaline (nmol/1) 
152 ±3 
102 ±2 
81 ± 2 
70 ±4 
0.56 ± 0.08 
1.95 ± 0.24 
84 4 
4.63 0.68 
2.27 0.36 
70 
6.44 
1.48 
4 <0.001 
0.90 <0.01 
0.25 <0.05 
~Difference between adrenaline and adrenaline + propranolol. 
NORADRENALINE 
~~:f 
300 
200 
100 
n=17 n=8 
L____j '-----.J 
before after before after 
COLD PRESSOR TEST ISOMETRIC EXERCISE 
Fig. 3. Plasma noradrenaline concentratien befare and after cold 
pressar and isometrie exercise tests, during infuslon of saline (0) 
and adrenaline (e). * P < 0.05, ** P < 0.01. 
change the blood pressure response, although it does 
anenuate the rise in heart rate [13,15,16]. In the present 
study adrenaline significantly augmented the pressar 
response ro cold exposure, and this effect was 
antagonized by propranolol. The data, therefore, indicate 
that aaivation of ~-adrenoceptors by adrenaline is 
capable of enhancing a physiological re.>-ponse mediated 
by tt-adrenoceptors. Thîs would fit with evidence from in 
vitro experiments that the release of transmitter 
noradrenaline is facilitated by adrenaline via acthmion of 
pre·,)'11aptic J>-adrenoceptors [2,5-8]. 
NORADRENALINE 
pg/ml 60or 
400 
200 
SAL AOR AOR 
PROPR 
Rg. 4. Plasma noradrenaline befere (open bars) and after (hatched 
bars) cold pressar test (n = 7), during infusion of saline (SAL), 
adrenaline (ADR) and adrenaline after administratian of prapranolo! 
(ADR PROPR). Levels after propranolal were lawer than with 
adrenaline alane, bath befare (P < 0,05) and after the test (P < 
0.01). 
Isometrie exercise has been used as another stimulus 
of sympathetic activity. This stimulus is known to increase 
heart rate and cardiac output, but the rise in blood 
pressure is mainty due to vasoconstriction, since it is 
prevented by blockade of a-adrenoceptors but nor by 
!>-receptor blockade [15,17-19]. With this stimulus, too, 
the a-adrenoceptor-mediated rise in blood pressure was 
augrnented in our subjects by adrenaline infusion. 
Theoretically the augrnented pressar responsetothese 
tests might have been due to increased post-synaptic 
sensitivity, although we do not know of data in the 
literature to support such a post·S}'Ilaptic mechanisrn. 
Moreover, this would not explain the increase in plasma 
noradrenaline observed. 
Adrenaline, in similar doses as we have given, has been 
found to increase plasma renin activity [20]. We cannot 
therefore exclude a facilitatory effect of adrenaline on 
noradrenaline release in our experiments via the 
activation of pre-synaptic angimensin II receptars [21]. 
However, in previous experiments we have shown that 
the ~-ag:onist-induced increase in plasma noradrenaline 
is mediated by J>,- rather than J3 1·receptors [22], whereas 
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stimulation of renin release ü; a ~ 1-effect [23-25]. 
Adrenaline infu'iion did not alter the heart rare 
response in the cold pressar and isometrie exercise tesL'i. 
This is nor unexpected, since the rise in heart rate is 
probably caused by vagal wirhdrawal rather than by 
sympathetic stimulation [19]. 
Plasma noradrenaline 
Adrenaline infusion caused a significant rise in plasma 
noradrenaline in uur subjects, and thL<i effect wao;; 
especially evident at the end of the cold pressar and 
isometrie exercise tests. This is funher support for the 
concept of adrenaline-mediared facilitation of neuronal 
noradrenaline release. 
That adrenaline increased plasma noradrenaline by a 
tyramine-like effect seems unlikely. Adrenaline has linie, 
if any, indirect sympathomimetic activit~l [26], and there 
wa<; no indication of tachyphyla..'\is in our experiments. 
Moreover, the effect of adrenaline wao; abolished by 
propranolol, and this can hardly be ascribed to its ability 
to block rhe neuronal uptake of adrenaline. Propranolol 
is veryweak in this respect [27] and we used the drug in a 
low dose. 
One could argue that the fall in diastolic pressure after 
adrenaline might have led to the observed increase in 
plasma noradrenaline, through barereflex stimulation of 
sympathetic activiry. However, the increase in heart rate 
and pulse pressure after adrenaline would be e.xpected 
to caose reflex Soppression of sympathetic activity [28]. 
Moreover, baroreflex-induced increased sympathetic 
activiry is an insofficient explanation for the observed 
enhancement of pressor responses to cold expo.-;ore and 
isometrie exercise àoring adrenaline infusion. 
The possibility of an alteration in the clearance rare of 
pla..<>ma catecholamines has also to be considered. 
Hpwever, adrenaline infusion has been reported to 
increase the clearance rate of plasma noradrenaline I 29 ], 
and this would tend to cause a drop in plasma 
noradrenalîne and not the rise observed here. 
Propranolol caoses a decrease of the clearance rate of 
plasma catecholamjnes [29]. This could explain why, in 
the present stody, the increased plasma level of 
adrenaline during adrenaline infusion was further 
increased by giving propranolol on top of adrenaline. In 
contrast, noradrenaline feil after propranolol. This 
soggests that, with high levels of circolating adrenaline, 
propranolol is capable of soppressing noradrenaline 
release. 
An increase in plasma noradrenaline after adrenaline 
infosion has been reponed by ethers using doses ranging 
from about 10 to 30 ng!min (0.05-0.16 fLmoVmin) per kg 
body weight [30-32]. This effect was not seen with higher 
doses of adrenaline [21,33]. By activaring pre-synaptic 
a.-adrenoceptors these high doses may have counteracted 
the facilitatory effect that is mediared by pre-synaptic 
13-adrenoceptors. 
Adrenaline that is infused or secreteà into the 
drculatîon may reach the pre-synaptic receptor sites on 
!:>ympathetic nerve endings either direaly via diffusion or 
indirectly after neuronal uptake and subsequem 
co-release tagether with noradrenaline [7]. 
So far, data on the effect of adrenaline infusion on both 
BP Response to Sympathetic Stimulation Vincent et al. 
plasma noradrenaline and on cardiovascular responses 
to sympathetic stimulation appear to suggest that 
pre-synaptic 13-adrenoceptors have a physiological role in 
blood pressure comrol. It has been proposed that these 
receptors are involved in the pathogenesis of 
hypeneosion [9] and in some therapeutic effects of 
j>-adrenoceptor blockade [34]. The results of rhe present 
study are in keeping with these hypotheses. 
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Chapter 5 
Is j3,-Antagonism Essential for the 
Antihypertensive Action of j3-Blockers? 
HIERONYMUS H. VINCENT, ARIE J. MAN IN "T VELD, FRANS BoOMSMA. 
FRANS H. M. DERKX. AND MAARTEN A. D. H. SeRALEKAMP 
SUMMARY Both nonselective ,8-blockers and ,81-selective blockers are effective antihypertensive 
agents. ,81-Blockade generally is considered to be responsible fortheir antihypertensive action, wbere-
as ,82-blockade is regarded as undesirable. These common assumptions notwithstanding, the mecha-
nism by which ,8-blockers lower blood pressure remains unknown. To examine the possibility that fj 2-
blockade may contribute to the antihypertensive action of ,8-blocker therapy, we studied the 
cardiovascular effects of compound ICI 118551, a J3rselective blocker. First, we showed that 50 mg 
t.i.d. orally is a ,82-selective dose. In contrast to propranolol, 80 mg t.i.d., .or atenolol, 100 mg once a 
day, 50 mg of ICI 118551 t.i.d. failed to block ,B 1~mediated inotropic stimulation and stimulation of 
renin by isoproterenol. We then performed a double-blind. placebo~controlled trial in patients with 
mild essential hypertension to compare this compound with propranolol. 80 mg t.i.d .. and showed 
that ICI 118551 significantly decreased systolic and diastolic blood pressure. This antihypertensive 
effect was demonstrated by direct as well as by indirect blood pressure measurements. Thus. contrary 
to prevailing thought. ,B1~blockade bas an antihypertensive effect independent of, and distinct from, 
,81-blockade. (Hypertension 9: 19S-203, 1987) 
KEY WoRDS • ,B 1~adrenergic receptors • .Bradrenergic receptors • presynaptic ,B~adrenergic 
receptors • ,B~adrenergic receptor antagonists • hypertension • isoproterenol • 
norepinephrine • renin 
N ONSELECTIVE ,8-blockers and ,81-selective blockers are both effective in lowering blood pressure. ,81-Adrenergic receptor blockade 
generally is thought to be essential for this effect, and 
. ,8,-blockade is often regardedas an undesirable proper-
ty that increases the chance of unfavorable side ef-
fects. 1 On the other hand. the mechanism by which 
,8-blockers lower blood pressure is not known, and ,81-
selective blockers also have their drawbacks. A ,8-
blockerthat is highly selective for ,82-adrenergic recep-
tors, IC! 118551 (DL-erythro-3-isopropylamine-1-
[7-methyl-4-indanyloxy]-2-butanol hydrochloride), is 
now available for clinical use. 2 In the present study we 
found that this compound has an antihypertensive ac-
tion in a dose that blocks the ,8,-adrenergic receptor-
medialed responses to isoproterenol but has no detect-
able effect on ,81-adrenergic receptor-medialed re-
sponses. 
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Patients and Methods 
Nineteen men (mean age. 36 years; age range. 21-
50 years) were studied. Their blood pressure in the 
outparient clinic was 140 to 160 mm Hg systolic and 90 
to 105 mm Hg diastolic. Routine clinical investiga-
tions revealed no cause for their hypertension. There 
were no signs of cardiac or renal disease. After the 
purpose and the procedures of the study had been ex-
plained, the patients gave their consent to participate. 
The study was approved by the hospita! ethica! review 
committee. Drug treatment. if any. was withdrawn 3 
weeks before the study. Nine patients (mean age. 35 
years) were enrolled in a double-blind. placebo-con-
trolled crossover trial comparing the ,8,-selective an-
tagonist !Cl 118551 with propranolol. Four of them 
had never been treated before. Patients were random-
ized to receive placebo, foliowed by !Cl 118551. pla-
cebo, and propranolol or placebo, foliowed by pro-
pranolol, placebo, and IC! 118551. Each treatment 
period lasled l week. !Cl 118551 (50 mg Li.d.) was 
given as a syrup. and propranolol (80 mg Li.d.) was 
given as tablets. Either placebo tabiets or placebo syr-
up was added to active treatment, and both were given 
in the placebo periods. 
Chapter 5 
.8,-BLOCKADE AND BLOOD PRESSVRE!Vincent et al. 
MEASUREMENTS 
Blood Pressure 
London School of Hygiene 
Sphygmomanometcr 
Autornatic Osclllometric 
Device 
lntra<:~rterlal 
I sopraterenol Test 
Rc'lln and Noreplnephrlne 
week 1 weck 2 
RUN IN 
• 
• 
• 
The times at which the various measurements were 
made are shown in Figure 1. The patients rested in the 
supine position for 15 minutes, and then three blood 
pressure measurements were made with a blind sphyg-
momanometer (London School of Hygiene). 3 Then a 
series of blood pressure measurements was made every 
5 minutes for 1 hour using an automatic oscillometric 
device (Accutorr, Datascope, Paramus, NJ. USA). 4 At 
the end of each week of placebo or active treatment. 
blood pressure was also measured intra-arterially. All 
blood pressure measurements were made 2 to 4 hours 
after the last dose of placebo or active drug. Blood 
samples were drawn from the arterialline. col!ected in 
chilled, heparinized tubes. and immediately centri-
fuged. Plasma was stared at - 20"C befare assay of 
active renin.' Plasma was deproteinized by 10% (vol/ 
vol) of 3 M trichloroacetic acid and stared at - 20"C 
fora maximum of 2 weeks befare assay of norepineph-
rine.6 
A continuous infusion of isoproterenol was given at 
the end of Week 1 on placebo and at the end ofWeeks 
2 and 4 on active drug. The dose of isoproterenol was 
increased every 15 minutes. Befare infusion and at the 
end of each dose step, intra-arterlal pressure, heart 
rate, a:!d duration of electromechanical systole' were 
measured and blood samples were drawn for delermi-
nation of plasma renin. norepinephrine. and potassium 
concentrations. 
The effects of the first 2 hours of active drug on 
blood pressure, heart rate, renin, and norepinephrine 
were assessed at the beginning ofWeeks 2 and 4. The 
• 
• 
• 
• 
week 3 weck 4 
• 
• 
• 
• 
• 
• 
F!GURE 1. Stud_v protocol. 
first dose of active drug was given 30 to 45 minutes 
after the isoproterenol infusion had been stopped. In 10 
patients isoprotereno1 was infused while they were un-
treated, after I week ofpropranolol, 80 mg t.i.d .. and 
after 1 week of atenolol, I 00 mg once daily. These 
data are presenled in order to campare the shifts of the 
isoproterenol dose-response curves caused by {32-
adrenergic receptor blockade with those caused by {31-
adrenergic receptor blockade. 
Data are presented as means ± SEM. Stuctent's 
paired t test was usl!d for comparison. A p value ofless 
than 0.05 was considered significant. 
Results 
Short-term Effects of I Cl 118551 and Propranolol 
Intra-arterlal pressure after the first dose of either 
IC! 118551 or propranolol did nol change in the 2 
hours that it was measured (Tab Je 1). In contrast, heart 
rate was Iowered by the two drugs. Plasma renin was 
significantly lowered by propranolol but nat by !Cl 
118551. Plasma norepinephrine rose after propranolol 
and was unchanged after IC! 118551 (Figure 2). 
Effects of a 1-Week Treatmeot witb ICI 118551 
or Propranolol 
After I week oftreatrnent systolic and diastolic pres-
sures, measured bath directly and indirectly. were sig-
nificantly reduced by !Cl 118551 as well as by pro-
pranolol (Table I, Figures 3 and 4). Heart rate and 
plasma renin were also reduced by bath drugs after 1 
TABLE 1. Short-Termand Long-Term Effects of/Cl l/8551 and Propranclol 
IC! 118551 (n - 9) Propranolol (n ~ 9) 
Befare 2 hr l wk Befare 2 hr 1 wk 
Intra-anerial blood pressure 
(mmHg) 
Systolic 157:!:2 160:!:5 150±3* 154±5 154±6 139=6t 
Diastolic 86±3 90±2 80±2* 84±3 86±9 72=3t 
Heart rate (beats/min) 68±3 61±3* 61 ±3* 69±3 59=3t 55o!o3t 
Norepinephrine (nmoVL) 1.78=0.20 1.65=0.20 1.55=0.17 1.37:!::0.20 1.95±0.24* 1.90±0.30* 
· Active renin (,u.U/ml) 2Le7 13±4 10:!:3* 21±7 7±6t 6=5t 
Values are means ± SEM. Blood pressure, norepinephrine, and renin measured before and 2 hours afterthe fitst dose 
and after 1 week of treatment. Data after l week were compared with conesponding data after placebo. 
*p < 0.05, tp < 0.01. compared with pretreatment values. 
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CHANGE IN •0,8 
NOREPI NE PH RI NE 
nmol/1 +0,6 
-0.11 
-0.6 
J 1 n 2h 
ICI 118.551 
l 1 1l 2 h 1 wk 
PROPRANDLOL 
FlGURE 2. Change in norepinephrine levels after short-term 
administrationandafter 1 weekoftreatmentwith/CJ/18551 or 
propranolol. Asterisk indicates significant difference (p<0.05) 
compared with placebo values. 
week of treatment. Plasma norepinephrine rose after 
propranolol but did not change after !Cl 118551 (see 
Figure 2) .. 
Isoproterenol Infosion Tests 
As described in Methods, !he effects of ,82-selective 
blockade on the responses to isoproterenol infusion 
were compared with the effects of ,81-selective block-
CHANCE IN 10 
SYSTOLIC 
PRESSURE 
mmHg 
CHANCE IN 10 
OIASTOLIC 
PRESSURE 
mmHg 
2 h' 
ICI 118.551 
'h' 
PROPRANDLOL 
FtGURE 3. lntra-arterial pressure response 2 hours and 1 
weekafter /C/118551 and after propranolol. Each line repre-
sems one patient. 
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ade by studying two groups of patients. One group 
received IC! 118551 and propranolol, !he other re-
ceived atenolol and propranolol. In !he first group in-
tra-arterial pressure befare isoproterenol infusion was 
160 ± 4187 ± 2 mm Hg without ,8-blocker treatment, 
150 ± 3/80 ± 2 mm Hg after I week of IC! 118551. 
and 139 ± 6/72 ± 3 mm Hg after I week of proprano-
lol. In the second group the pressure was 152 ± 41 
77 ± 3 mm Hg without treatment, 130 ± 5162 ± 2 mm 
Hg after 1 week of atenolol, and 130 ± 5/66 ± 2 mm 
Hg after I week of propranolol. Thus, !he blood pres-
sure values befare isoproterenol infusion were campa-
rabie in !he two groups. 
!Cl 118551 did not alter !he inotropic effects of 
isoproterenol (i.e .. shortening of electromechanical 
systole [QS,I] and rise in systolic pressure; Figure 5). 
Neither did it alter !he effect of isoproterenol on plas-
ma renin (Figure 6). In contrast. these responses were 
shifted by a dose factor of eight or more by both ateno-
Io I and propranolol. The beart rate response was sbift-
ed by a dose factor of about !wo after IC! 118551, by a 
factor of four after atenolol, and by a factor of 16 after 
propranolol. The effects of isoproterenol on diastolic 
pressure. plasma norepinephrine, and plasma potas-
siurn were abclisbed by IC! !18551 and propranolol. 
After atenolol treatment these effects were shifted by a 
dose factor of two. 
Discussion 
132-Selectivity of ICI 118551 
IC! 118551 is a highly selective and specific ,82-
adrenergic receptor antagonist in vitro. 2 The present 
study shows that !Cl 118551, given in a dosage of 50 
mg t.i.d., is also ,82-selective in vivo. The drug antago-
nized the effects of isoproterenol on diastolic pressure. 
plasma norepinephrine, and plasma potassium, which 
are ,82-adrenergic responses. S-ll !Cl 118551 did not 
antagonize the rise in systolic pressure or the shorten-
ing of electromechanical systole (QS,I) caused by iso-
proterenol. which are inotropic responses mediated by 
,81-adrenergic receptors. Neither did it antagonize !he 
effect of isoproterenol on plasma renin. This effect of 
isoproterenol also is regarded as a ,81-adrenergic re-
sponse. 12 The chronotropie effect of isoproterenol, 
which is a mixed ,13 1/,82-adrenergic response. 13 was an-
tagonized by a factor of only two by IC! 118551, as 
compared withafactor of 16 by propranolol. When the 
shifts of !he ,81-adrenergic responses (systolic pres-
sure, QS,l, renin) and of !he ,8,-adrenergic responses 
(diastolic pressure, norepinephrine, potassium) caused 
by !Cl 118551 were compared with the shifts caused 
by atenolol, !he ,82-selectivity of !Cl 118551 was even 
greater than the ,81-selectivity of atenoio I, at least in tbe 
doses we have used. 
Antibypertensive Elfeet of ICI 118551 
The main finding ofthis study is that IC! 118551, in 
a ,82-selective dose, lowered blood pressure. This ob-
servation is at varianee with earlier reports by Robb et 
al. 14 and by Dablof et al." wbo could not demonstrate 
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ABC D E ABC D 
blind automatic 
sphygmomanometry 
E B C D E 
intra artcrinl 
measurcment 
FIGURE 4. Average blood pressure befare 
treatment (run in; A). after placebo (8}, after 
placebo (wash out; C). after ICII/8551 (D). 
after propranolol (E). Single (p<0.05) and 
double (p<O.OJ) asterisks indicate significant 
difference compared with placebo. 
CHANGE IN REN IN Ok! 
CHANGE IN ELECTROMECHANICAL SYSTOLE [QS, I) 111sec 
l.S 
CHANGE IN SYSTOUC PRESSURE mmHg 
CHANGE IN OIASTOLIC PRESSURE mmHg 
35 lSO 
ngkg-Tmin-1 
ISOPROTERENOL DOSE 
35 350 
ngkg lmin 1 
CHANCE IN NÖREPINEPHRINE nmol/1 
•1.'[ •0.8 
>1).4 
o.o 
o.• 
CHANGE IN POTASSlUM mmo1 11 
0.0! '/-.._ 0.1 Î-<1•-hL .... kr 
0.2 r'\ t r r 
0.3 ~ 
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o.s 
3.5 35 350 
ngkg lmln 1 
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35 350 
ngkg 1min 1 
F!GURE 5. Isoproterenol dose-response curves befare ereat-
ment (O) and after treatment with IC/118551 (À), atenoio I("), 
or propranolol (D). 
FIGURE 6. Jsoproterenol dose-response curves before treat-
ment(O)andaftertreatmentwith!CIII855I (A), atenoloi(V), 
or propranolol (0). 
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an antihypertensive effect of IC! I I 855 I. The mean 
age of the patients (48 and 46 years. respectively) in 
those two studies was higher than that in our study (35 
years). Moreover, the patients in the two negative 
studies had all been treated previously. whereas four of 
our patients had never been treated before. This differ-
ence suggests that !heir patients had hyperlension of 
Jonger duration. It could be that ,B,-blockade is more 
effective in an earlierstage of the disease. lt mayalso 
be important that Dablof et al." did not use placebo 
controls after the run-in phase. This omission might 
obscure the antihypertensive effect of IC! 118551 by a 
gradual return of hypertension, not only during the 
run-in phase but also during IC! l 1855 I treatment. 
Mechanism of Action of IC! 118551 
The mechanism by which ,B-blockers lower blood 
pressure remains a matter of debate. tb-t9 Cardiac, vas-
cular, or hormonal changes and effects on body !luid 
volumes have been suggested to play a role. 20·" ,B-
B lockers with different ancillary proporties. such as 
partial agonist activity, ,81-adrenergic receptor selec-
tivity. or hydrophilicity, alllower blood pressure. ,81-
Adrenergic receptor blockade generally is considered 
the common denominator of this effect. The current 
study, however, shows that selective blockade of ,B,-
adrenergic receptors also lowers blood pressure. Firm 
conclusions on the anatomical site of this /32-adrener-
gic receptor, centrally, presynaptically, or postsynap-
tically in the heart, kidneys, orblood vessels. cannot 
be drawn from our data. 
Currently, there is little evidence that ,82-adrenergic 
receptars in the central nervous system are involved in 
blood pressure regulation. We have no information on 
changes in cardiac output, vascular resistance. or body 
!luid volumes after IC! I I 8551 treatrnent. The drug did 
lower the basal levels of plasma renin. which might 
have contributed to its antihypertensive effect. Plasma 
norepinephrine rose with propranolol treatment but did 
notchange with IC! 118551 treatment. This difference 
might be explained by different effects of the two 
drugs on the clearance of plasma norepinephrine. 
Heart rate (and therefore probably cardiac output) feil 
more during propranolol than during !Cl 118551 treat-
ment. Indeed. changes in plasma norepinephrine level 
during ,B-blockade seem to reflect changes in the 
clearance of this·neurotransmitter rather than changes 
in its release. 17• 22- 24 
One of the theories explaining the antihypertensive 
effect of ,B-blockers implicates a role for presynaptic 
,8,-adrenergic receptors, which serve to facilitate nor-
epinephrine release from sympathetic nerves. Activa-
tion of these receptors by epinephrine might cause 
hypertension."· 26 Blockade of these receptors would 
decrease norepinephrine release and thereby lead to 
diminished activation of cardiac ,B-adrenergic recep-
tors and vascular a-adrenergic receptors. This mecha-
nism might account for the antihypertensive effect of 
,8,-blockade, although it does not provide an explana-
tion for the antihypertensive action of ,81-blockade. 
The rise in renin in response to isoproterenol was not 
antagonized by IC! 118551. which confirms its ,B,-
selectivity. Yet the drug lowered the basal level of 
renin. Again. this response may be explained by pre-
synaptic inhibition of norepinephrine release. leading 
to diminished activation of postsynaptic {3 1-adrenergic 
receptors in the kidney. 
Whatever the precise mechanism of the fall in blood 
pressure after ,B,-blockade, our data demonstrate that 
,81-blockade is no always essential for the antihyper-
tensive effect of ,B-blocker therapy. 
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SUMMARY 
Adrenergic stimulation of renin release is known to be mediated 
by activatien of beta-l adrenoceptors on juxtaglomerular cells. 
However, when systemically infused, bath non-selective and beta-2 
selective agonists increase renin release. In order to 
investigate the mechanism whereby beta-2 stimulation may increase 
renin, we compared the effects of infusion of the beta agonists 
prenalterol (beta-1), salbutamol (beta-2) and isoprenaline (beta-
1 plus beta-2) on plasma renin in subjects with mild essential 
hypertension. Isoprenaline was infused befare and during 
treatment with the betablockers atenolol (beta-1), ICI 118551 
(beta-2) and propranolol (beta-1 plus beta-2). The effect on 
plasma renin was compared with the effects on electromechanical 
systole (QS2-index) and diastolic blood pressure, as a measure of 
activatien of beta-l and beta-2 adrenoceptors respectively. The 
concomitant changes in plasma noradrenaline were also measured. 
For a given shortening of the QS2-index, the rise of renin 
in response to prenalterol was less than after salbutamol and 
isoprenaline. Prenalterol had na effect on diastolic pressure. 
For a given decrease in diastolic pressure, the rise of renin in 
response to salbutamol was similar to that after isoprenaline. 
The dose related rise in renin after salbutamol and isoprenaline 
was closely and linearly correlated with the rise in 
noradrenaline. This was associated with a drop in diastolic 
pressure at low agonist doses but there was na further change in 
diastolic pressure at higher doses. These data indicate that 
beta-2 receptor activatien is capable of stimulating renin and 
that this beta-2 effect is nat solely caused by barereflex 
mediated sympathetic stimulation in response to vasodilatation. 
The antagonistic effect of bath atenolol, in a beta-l selective 
dose, and propranolol on the isoprenaline induced rise in renin 
was equal to their antagonistic effect on the isoprenaline 
induced shortening of the QS2-index. In contrast, selective beta-
2 blockade with ICI 118551 had little antagonistic effect on 
these responses to isoprenaline. Thus, the beta-2 mediated rise 
in renin depends on beta-l receptor activation. Baseline plasma 
levels of renin were decreased by all three betablockers. The 
data, taken together, are compatible with the view that beta-2 
agonists, through activatien of renal presynaptic beta receptors, 
increase the release of transmitter noradrenaline, which acts on 
postsynaptic beta-l receptars to stimulate the release of renin. 
Key words: renin, noradrenaline, presynaptic beta adrenoceptors, 
beta adrenoceptor agonists, betablockers 
39 
Chapter 6 
INTRODUeTION 
From in~vitro experiments it appears that the release of renin 
from juxtaglomerular cells induced by beta adrenoceptor agonists 
is mediated by beta-l adrenoceptors [1-3]. Renin release elicited 
by low frequency stimulation of the renal nerves or by infusion 
of beta agonists in intact animals also depends on beta-l 
receptor activatien [4-6]. In man, exercise induced renin release 
is also a beta-l effect [7-9] and, according to most 
investigators, the same is true for the increase in plasma renin 
in response to beta agonist infusion [ for review of the 
literature see ref. 10]. Some observations, however, indicate 
that plasma renin is increased by beta-2 agonists and not by 
beta-l selective agonists [11-14]. The present study was 
undertaken to clarify the mechanism whereby beta-2 agonists may 
stimulate renin in man. We have previously found that plasma 
noradrenaline is increased by systemic infusion of beta agonists, 
which is an indication of stimulated sympathetic activity. This 
effect appears to be mediated by beta-2 recepters [15]. It seems 
therefore possible that the increase in renin by infusion of 
beta-2 agonists is an indirect effect, via increased sympathetic 
nerve_stimulation of beta-l recepters on juxtàglomerular cells. 
SUBJECTS AND METHOOS 
Forty subjects with mild essential hypertension were studied. 
Their blood pressure in the outpatient clinic ranged from 140 tot 
160 mmHg systolic and from 90 tot 105 mmHg diastolic. They showed 
no signs of cardiac or renal disease and were not on any medical 
treatment. All subjects had given their informed consent and the 
study protocol was approved by the hospital ethical review 
committee. 
Isoprenaline was given by continuous intraveneus infusion in 
increasing doses to 21 male subjects. In 10 subjects ( aged 20-45 
yr) each dose step lasted 30 min ( group I) and in 11 subjects 
the dose was 1ncreased èvery 15 min ( group II) . In group I the 
isoprenaline infusion was given before and after 7 days treatment 
with the non-selective beta antagonist propranolol ( 80 mg 
t.i.d.) and also after 7 days treatment with the beta-l selective 
antagonist atenolol {100 mg once daily). In group II isoprenaline 
was infused before and after 7 days treatment with propranolol 
{80 mg t.i.d.) and also after 7 days treatment with the beta-2 
selective antagonist ICI 118551 [16] (50 mg t.i.d.), in random 
order. The beta-l selective agonist prenalterol was given 
intravenously in increasing doses to 9 subjects (aged 19-45 yr, 5 
males) (group III). Each dose was infused over 5 min at 15 min 
intervals. The beta-2 selective agonist salbutamol was given by 
continuous intraveneus infusion in increasing doses to 12 
subjects (aged 16-50 yr, 8 males), each dose step lasting 15 min. 
A 20-gauge cannula was inserted into the radial artery for 
blood sampling and blood pressure measurements. Infusions were 
given via a forearm vein with the patient resting supine. Prior 
to each beta-agenist infusion, saline was infused for 30-45 min 
at a rate of 22 mljhr until heart rate and blood pressure were 
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stable. Blood samples for renin and noradrenaline were takeri just 
before the beta-agenist infusion was started and at the end of 
each dose step. 
Heart rate and intra-arterial.pressure were continuously 
recorded. The duration of electromechanical systole corrected for 
heart rate (QS2-index) was measured according to Lewis et al 
[17]. Inotropic stimulation, as reflected by a shortening of the 
QS2-index was taken as a measure of beta-l receptor stimulation. 
Vasodilatation, as reflected by a decrease in diastolic arterial 
pressure, was taken as a measure of beta-2 receptor stimulation. 
Blood was collected into chilled heparinized tubes and 
immediately centrifuged. For the measurement of noradrenaline the 
plasma was then deproteinized with 10% trichloroacetic acid. The 
deproteinized samples were stored at·-2o0 c for no longer than 2 
weeks before assay. Renin ( the enzymatically active form) was 
measured by RIA as described previously [18] and noradrenaline 
was measured radioenzymatically, using phenylethanol-N-
methyltransferase (PNMT) and (3H)-S-adenosyl-L-methionine [19]. 
Data are presented as mean and SEM. Changes from baseline were 
analysed by student's t-test for paired observations. A p-value 
of less than 0.05 was considered to be significant. 
RESULTS 
Baseline plasma renin and noradrenaline levels are shown in Fig. 
1. They were not different in the 4 groups of subjects before 
betablocker treatment. Renin was decreased by all three 
betablockers i.e. propranolol, atenolol and ICI 118551. 
Noradrenaline was increased by propranolol and was not altered by 
atenolol and ICI 118551. 
Fig. 2 compares the effects of isoprenaline, prenalterol and 
salbutamol. At the highest dose, heart rate ( not shown) was 
increased by 44 (SEM 5) beatsjmin with isoprenaline, by 24 (2) 
beatsjmin with prenalterol and by 22 (3) beatsjmin with 
salbutamol. Renin rose by 128 (34) % (p<O.OOl) at the highest 
dose of isoprenaline, by only 68 (25) % (p<0.05) at the highest 
dose of prenalterol and by 100 (39) % (p<O.Ol) at the highest 
dose of salbutamol. For a given shortening of the QS2-index the 
rise in renin in response to prenalterol was less than after 
isoprenaline and salbutamol. Prenalterol had no effect on 
diastolic pressure. For a given decrease in diastolic pressure 
the rise in renin in response to salbutamol was similar to that 
after isoprenaline. Thus, not only beta-l receptor activatien but 
also beta-2 receptor activatien caused an increase in renin. 
The responses of renin and the QS2-index to isoprenaline 
were antagonized by both the beta-2 selective antagonist ICI 
118551 and by the non-selective beta antagonist propranolol but 
much less so by ICI 118551 than by propranolol (Fig. 3). The 
effect of isoprenaline on diastolic pressure was abolished by 
both ICI 118551 and propranolol. Thus, the rise in renin in 
response to isoprenaline depended on beta-l receptor stimulation. 
This is confirmed by the data shown in Fig. 4. The responses of 
renin and the QS2-index to isoprenaline were antagonized to a 
similar extent by the beta-l selective antagonist atenolol and 
the non-selective beta antagonist propranolol, whereas the effect 
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on diastolic pressure was much less antagonized by atenolol than 
by propranolol. 
As can be seen in Fig. 5, the effect of isoprenaline and 
salbutamol on renin was closely and linearly correlated with the 
effect on noradrenaline. Moreover, for a given increase in 
noradrenaline, the increase in renin was similar with both drugs. 
This, together with the results obtained with isoprenaline after 
treatment with the beta-l selective blocker atenolol, suggests 
that beta-2-mediated stimulation of noradrenaline release with 
subsequent activatien of beta-l recepters is the mechanism that 
underlies the effect of both salbutamol and isoprenaline on 
renin. The beta-l selective agonist prenalterol increased renin 
but had little effect on noradrenaline, which suggests that in 
this case the effect on renin is caused by stimulation of beta-l 
recepters by prenalterol itself. 
It is further of interest that the diastolic blood pressure 
was decreased by the lowest doses of isoprenaline and salbutamol 
and that this was accompanied by little increase in 
noradrenaline. In contrast, diastolic pressure was not further 
decreased at higher doses of isoprenaline and salbutamol, whereas 
the largest increments in noradrenaline occurred at these doses 
(Fig. 5). 
DISCUSSION 
By measuring the effects of various beta agonists and antagonists 
on plasma renin and by comparing these effects with haemadynamie 
responses that are known to be selectively mediated by either 
beta-l or beta-2 receptors, we could demonstrate that renin is 
increased by beta-2 stimulation with salbutamol and decreased by 
beta-2 blockade with ICI 118551. Beta-l stimulation in addition 
to beta-2 stimulation, as occurs with isoprenaline, had little 
extra effect on renin. Also, isolated beta-l stimulation with 
prenalterol had only a modest effect on renin as compared with 
salbutamol and isoprenaline. Yet, the results obtained with 
isoprenaline after pretreatment with either the selective beta-l 
blocker atenolol, the selective beta-2 blocker ICI 118551 or the 
non-selective betablocker propranolol indicate that beta-2 
agonist infusion in the intact individual causes an increase in 
renin via stimulation of beta-l recepters and that this beta-l 
effect is not a consequence of insufficient selectivity of the 
beta-2 agonist being used. 
We observed a modest increase of renin in response to 
prenalterol but others did not see any effect [11,13,14]. 
Prenalterol is a partial beta-l agonist. Because of this, the 
effect on renin may depend on the prevailing sympathetic nervous 
outflow to the kidney. Prenalterol may have little effect on 
renin when the prevailing sympathetic activity is high. 
Theoretically, there are several ways in which beta-2 
receptor stimulation may cause an increase in renin. Firstly, one 
has to consider that juxtaglomerular cells may be endowed with 
beta-2 receptors, and that stimulation of these recepters may 
lead to increased release of renin. However, the antagonistic 
effect of the beta-l selective blocker atenolol and the non-
selective betablocker propranolol on the response of renin to 
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isoprenaline was correlated with the degree of beta-l blockade 
(response of the QS2-index) and nat with the degree of beta-2 
blockade (response of diastolic blood pressure) • This argues 
against a role of beta-2 receptors.located on juxtaglomerular 
cells. 
Secondly, plasma potassium is known to be lowered in a dose 
dependant way by infusion of beta-2 agonists. At the highest 
doses we have used bath isoprenaline and salbutamol lowered 
plasma potassium by approximately 0.5 mmoljl [15]. Dietary 
potassium deprivation may be associated with in increase in renin 
[20]. However, experiments with isolated perfused rat kidneys 
have demonstrated that although renin secretion is increased 
after potassium depletion, changes in the potassium concentratien 
of the perfusate were without effect [21]. Experiments with rat 
kidney slices have also shown that variations of extracellular 
potassium concentratien from 2.5 to 4.0 mmol/1 had no effect on 
renin secretion [22]. More importantly, studies in dogs have 
shown that renin in plasma is increased by adrenaline infusion 
when the plasma level of potassium is kept constant and that this 
effect on renin is not greater when the potassium level is nat 
maintained [23]. Isoprenaline infusion in dogs has also been 
reported to increase renin in the absence of changes in plasma 
potassium [24]. 
A third possibility is that renin release is stimulated as a 
consequence of activatien of vascular postsynaptic beta-2 
receptors. Activatien of these vascular receptars causes 
vasodilatation and a lowering of blood pressure. This in turn may 
stimulate renin release through the renal baroreceptor mechanism 
or through the arterial barereflex induced increase in 
sympathetic activity. However, stimulation of the renal 
baroreceptor mechanism is in itself insufficient to explain the 
rise of renin in response to beta-2 agonist infusion, since this 
response depended on stimulation of beta-l receptors. 
Furthermore, with infusion of salbutamol and isoprenaline the 
plasma levels of renin and noradrenaline rose in a dose dependent 
way, whereas diastolic pressure decreased only at the lowest dose 
but showed na further decrease at higher doses. Also, bath renin 
and diastolic pressure were decreased by the beta-2 selective 
blocker ICI 118551. Thus, barereflex mediated stimulation of 
renin release is unlikely to be the sole cause of the rise of 
renin in plasma. 
Finally the rise in renin after beta-2 agonist infusion may 
be explained by presynaptic facilitation of sympathetic 
transmitter release within the kidney. In-vitro experiments have 
shown that activatien of presynaptic beta-2 receptars located on 
sympathetic nerve endings has a facilitatory effect on 
noradrenaline release in various tissues, including the kidney 
[25,26]. In our subjects plasmareninwas increased in parallel 
with noradrenaline after beta-2 agonist infusion. It seems 
therefore likely that at least part of the rise in renin is 
caused by increased release of transmitter noradrenaline. Indeed, 
in dogs it has been shown that the increase in renin after 
systemic infusion of adrenaline in a low concentratien depends on 
intact renal innervation and that the effect on renin is 
antagonized by beta-l as well as by beta-2 antagonists. From 
these observations it was concluded that beta-2 receptor 
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stimulation by adrenaline leads to increased renin through 
presynaptic facilitation of noradrenaline release in the kidney 
[27]. The observation that in our subjects plasmareninwas 
lowered by the beta-2 selective blocker ICI 118551 as well as by 
the beta-l selective blocker atenolol is in accordance with the 
above study in dogs. That plasma noradrenaline was nat lowered by 
ICI 118551 is nat in contradietien with an effect on presynaptic 
beta receptors, since the clearance of noradrenaline is decreased 
after betablocker treatment [28]. 
We conclude that bath beta-l and beta-2 adrenoceptor 
activatien by systemic infusion of beta agonists can increase 
renin release. The effect of beta-2 receptor activatien on renin 
is most likely an indirect one; it depends on activatien of 
postsynaptic renal beta-l receptars by transmitter noradrenaline. 
Although a reflex increase of sympathetic tone in response to 
vasodilatation may contribute to this indirect effect, it is 
likely that activatien of presynaptic renal beta-2 receptars with 
subsequent facilitation of sympathetic transmitter release is the 
more important underlying mechanism. 
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Fig. 2. Effects of the beta agonists isoprenaline ( non-
selective), prenalterol ( beta-lselective) and 
salbutamol (beta-2 selective) on renin and on duration of 
electromechanical systole and diastolic blood pressure. 
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Fig. 3. Effects of the beta agonist isoprenaline on renin and on 
duration of electromechanical systole and diastolic pressure. 
A: untreated 
B: after ICI 118551 (beta-2 selective blocker) 
C: after propranolol (non-selective betablocker) 
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Fig. 4. Effects of the beta agonist isoprenaline on renin and on 
duration of electromechanical systole and diastolic pressure. 
A: untreated 
B: after atenolol (beta-1 selective blocker) 
C: after propranolol ( non-selective betablocker) 
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GENERAL DISCUSSION 
As discussed in the introduetion (Chapter 1), several in-vitro 
studies and a number of animal studies have provided evidence for 
the existence of so-called presynaptic beta adrenoceptors. These 
are beta-2 type recepters located on sympathetic nerve endings, 
which regulate the amount of transmitter released in respons to 
nerve stimulation. Activatien of these presynaptic recepters by 
the hormone adrenaline facilitates the release of the 
neurotransmitter, noradrenaline. In this way presynaptic beta 
recepters could be involved in blood pressure regulation, and it 
has been speculated that presynaptic beta blockade could account 
for the antihypertensive effect of betablocker therapy. 
The questions addressed in this thesis are the following: 
1) Can presynaptic beta recepters be shown to be functionally 
active in intact man. 2) What, if any, is their physiological 
rdle. 3) Are these receptars involved in the antihypertensive 
effect of betablocker therapy. 
Effect of beta agonists and antagonists on plasma noradrenaline 
Our first approach was to study the effects of beta agonists and 
antagonists with different beta-l 1 beta-2 selectivity (Chapters 
2 and 3). Beta-2 receptor activatien with isoprenaline or 
salbutamol caused a 75% rise in plasma noradrenaline 
concentration. Beta-l receptor activatien had no such effect. Our 
finding that isoprenaline increases plasma noradrenaline has been 
confirmed by Goldstein et al [1]. These authors, using the same 
doses as we did, found an 81% rise of plasma noradrenaline. They 
further found that plasma adrenaline was unchanged or decreased, 
which may be taken as evidence that isoprenaline led to 
noradrenaline release from sympathetic nerves rather than from 
the adrenals. These observations are taken as evidence for 
presynaptic facilitation of neuronal noradrenaline release. With 
regard to this interpretation three possible points of criticism 
must be considered. First, beta-2 receptor activatien causes 
vasodilatation and may thereby lower blood pressure. This in turn 
may cause stimulation of sympathetic nerveus activity via the 
arterial barereflex mechanism. In our apinion this is unlikely 
for several reasons. It is questionable whether barereflex 
mediated changes in sympathetic activity are ever reflected by 
changes in noradrenaline as large as in our study [2]. 
Furthermore, the increase in blood pressure was small (sometimes 
blood pressure actually increased) and heart rate and pulse 
pressure rose. The latter would rather have the opposite effect 
on the baroreflex. A further argument that the isoprenaline 
induced rise in plasma noradrenaline is not mediated by the 
barereflex comes from a recent study by Arnold et al [3]. These 
authors administered the anticholinergic drug atropine befare 
infusion of isoprenaline and found that the heart rate response 
curve was shifted to the left, implying the presence of a reflex 
increase in vagal tone during isoprenaline infusion. Thus a 
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reflex withdrawal of sympathetic tone may be inferred, and this 
would cause a fall rather than a rise in plasma noradrenaline 
concentration. 
Second, a rise in plasma noradrenaline could result from a 
decrease of its roetabolie clearance rate. However, beta 
adrenoceptor stimulation has been found to increase, not 
decrease, noradrenaline clearance [4]. The finding by Goldstein 
et al that, during isoprenaline infusion, plasma adrenaline 
concentratien tended to fall [1] is indeed an indication that 
catechelamine clearance was increased. 
Third, beta adrenoceptor activatien raises plasma renin and 
will thereby lead to higher angiotensin-II concentrations. 
Angiotensin-II, like adrenaline, has been shown to exert a 
presynaptic facilitatory effect on noradrenaline release [5]. The 
rise in noradrenaline after beta agonist infusion might therefore 
be secondary to its effect on renin. This is supported by the 
observation by Majewski et al [6] that, in a pithed rabbit, 
inhibition of noradrenaline release by propranolol no longer 
occurred after pretreatment with the angiotensin converting 
enzyme inhibitor captopril. He suggested that the inhibition of 
noradrenaline release after propranolol was in fact due its 
effect on renin rather than to blockade of presynaptic beta 
receptors. In our studies, however, the effects of isoprenaline 
on renin and on noradrenaline were clearly dissociated. Atenolol 
and propranolol lowered plasma renin concentratien to the same 
extent (see Chapter 6), yet atenolol had little effect on the 
noradrenaline response to isoprenaline, whereas propranolol 
abolished this response. 
The data presented in Chapters 2 and 3 and the reports from 
the literature discussed above provide evidence that beta-2 
adrenoceptor activatien can stimulate or facilitate noradrenaline 
release from sympathetic nerves in a direct way. 
Effects of adrenaline on plasma noradrenaline and on 
cardiovascular responses 
The question regarding the physiological significanee of 
presynaptic beta-2 receptars was addressed in a number of 
experiments where we studied the effects of the natura! beta-2 
agonist, adrenaline, on the response to sympathetic nervous 
stimulation. Cold exposure ( one hand in ice water) and isometrie 
forearm exercise were used to evoke a sympathetic nervous 
response, which was reflected by a rise in blood pressure. 
Adrenaline was infused in a dose that caused plasma adrenaline 
concentratien to rise to 800 pgjml, which is within the 
physiological range. Similar concentrations are reached during 
moderate levels of stress [7]. During adrenaline infusion base 
line heart rate rose by 8 beats/min and diastolic pressure fell 
by 10 mmHg. Plasma noradrenaline rose by 30%. The blood pressure 
response to the cold pressar and isometrie exercise tests was 
significantly increased. The rise in heart rate, which is 
attributed to a decrease of parasympathetic activity, was not 
affected. After intraveneus injection of propranolol, 0.5 mg, 
baseline heart rate and blood pressure returned to control 
levels. The observation that heart rate was not lowered below 
control levels is important, since this indicates that 
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propranolol in this dose blocked beta-2 receptars selectively. 
After propranolol the amplification by adrenaline of the blood 
pressure response to sympathetic stimulation was abolished. 
Thus, adrenaline, in physiological concentrations, increases 
noradrenaline and amplifies the blood pressure response to 
sympathetic nerve activity. This effect is mediated by beta-2 
type receptors. 
A recent study by Floras et al [8] corroborates this 
finding. These authors reported that infusion of either 
isoprenaline ar adrenaline into the forearm, in doses that caused 
na systemic effects, augmented the vasoconstrictor response to 
another sympathetic stimulus, lower body negative pressure. The 
effect of adrenaline outlasted the duration of the infusion bv at 
least 30 min, which argues for the possibility that an acute -
elevation of plasma adrenaline concentratien causes a longlasting 
increase in vascular resistance. This longlasting effect is 
likely to be due to adrenaline uptake into the sympathetic neuron 
and subsequent 'co-release' tagether with noradrenaline. 
Interestingly, adrenaline attenuated the vasoconstrictor response 
to infused noradrenaline. This may be taken as evidence that the 
augmented blood pressure response to sympathetic stimulation 
during adrenaline infusion was indeed due to increased 
noradrenaline release rather than to an increased alpha receptor 
sensitivity. Further confirmatien comes from a study from our own 
laboratory [9]. In normal volunteers intraveneus infusion of 
adrenaline, 15 ngjmin per kg body weight, raised plasma levels 
of adrenaline to 250 pgjml, corresponding to mild farms of 
stress. In this study the dose of adrenaline was lower than in 
our previous experiments, but again the blood pressure response 
to cold exposure and isometrie exercise was augmented. Moreover, 
resting blood pressure was significantly increased for up to 18 h 
after the infusion had been stopped. All these data are in 
accordance with a physiological role for adrenaline to facilitate 
the release of noradrenaline from sympathetic nerves. This effect 
may last much langer than the elevation of plasma adrenaline. 
Effect of a beta-2 selective antagonist on blood pressure 
If it is true that adrenaline raises blood pressure through 
presynaptic beta-2 type receptors, beta-2 receptor blockade is 
expected to have a blood pressure lowering .effect. The question 
wether blockade of presynaptic beta-2 receptars lowers blood 
pressure was addressed in a clinical trial, described in Chapter 
5. In 9 subjects with essential hypertension, the effects of a 
beta-2 selective antagonist ICI 118551 and of the non-selective 
antagonist propranolol were compared with placebo according to a 
randomized crossover design. ICI 118551 did not block the beta-l 
receptor mediated inotropic stimulation of the heart and 
stimulation of renin by isoprenaline, but it abolished a number 
of beta-2 receptor mediated responses, i.e. the fall in diastolic 
pressure, the rise in noradrenaline and the fall in plasma 
potassium. Two hours after ingestion of either ICI 118551 or 
propranolol, heart. rate had decreased and blood pressure was 
unchanged. After one week, however., bath. systolic and diastolic 
pressure, whether measured indirectly ar intra-arterially, were 
significantly decreased by beta-2 selective blockade as well as 
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by propranolol. Furthermore, both drugs lowered heart rate and 
renin. Thus, a camparisen of beta-2 selective blockade with non-
selective betablockade showed that the time course and pattern of 
the responses of heart rate, blood.pressure and renin were in 
fact very similar. The data are compatible with presynaptic beta-
2 blockade leading to inhibition of noradrenaline release and a 
fall in blood pressure. 
At first sight the observation that, generally, beta-l 
selective blockers and non-selective betablockers lower blood 
pressure equally well seems to argue against a role of 
presynaptic beta-2 blockade. However, it is likely that, in the 
doses clinically used, beta-l selective blockers also bleek 
presynaptic beta recepters to a significant extent. On the ether 
hand, in our study the magnitude of the fall in blood pressure 
tended to be greater after propranolol than after ICI 118551. 
This would suggest that beta-l blockade does contribute to the 
antihypertensive action of betablocker therapy. 
It has further been argued that presynaptic inhibition of 
noradrenaline release ought to be reflected in a fall in plasma 
noradrenaline concentration. In our study we found a tendency for 
plasma noradrenaline to fall after ICI 1181551 but this was not 
significant. After propranolol noradrenaline was actually 
increased. It must be pointed out, however, that sametimes plasma 
noradrenaline may not accurately reflect noradrenaline release 
[10,11]. Specifically, it has been reported that after beta 
blockade noradrenaline clearance is decreased. In some studies 
betablocker therapy did lower the noradrenaline release rate and 
urinary catechelamine excretion, especially in these subjects who 
responded to betablocker therapy with a fall in blood pressure 
[12-15]. Furthermore, an increase in noradrenaline after 
propranolol may not only be explained by an effect on 
noradrenaline clearance but also by a temporary barereflex 
mediated increase in sympathetic nerveus tone to counteract the 
consequences of cardiac beta-l receptor blockade. Such an event 
is not incompatible with concomitant presynaptic inhibition of 
noradrenaline release. 
Another criticism against a role of presynaptic beta blockade 
in the antihypertensive action of betablockers concerns the 
change in pheripheral vascular resistanceA Whereas presynaptic 
blockade of noradrenaline release would be expected to lead to a 
fall in vascular resistance, most studies have in fact reported 
an increase. However, as has been pointed out by Man in't Veld 
and Schalekamp [16], the antihypertensive effect of betablocker 
therapy may be delayed by an initial increase in vascular 
resistance, but at the time blood pressure is falling this fall 
is actually parallelled by a fall in vascular resistance. 
Effects of beta agonists and antagonists on plasma renin 
From the study described in Chapter 5 we concluded that beta-2 
blockade leads to a fall in renin. Data in the literature, 
regarding the beta receptor subtype involved in renin release, 
are somewhat contradictory. This prompted us to analyse in detail 
the renin response to beta receptor agonists and antagonists with 
different selectivity. The results are presented in Chapter 6. 
Effects of isoprenaline befere and after treatment with the 
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antagonist atenolol (beta-1), ICI 118551 (beta-2) or propranolol 
(non-selective beta antagonist) were examined. The response of 
renin was compared to the shortening of cardiac electromechanical 
systole and to the fall in diastolic arterial pressure as 
parameters of beta-l and beta-2 receptor activatien respectively. 
This camparisen of different betablockers indicated that the 
isoprenaline induced rise in renin was mediated by beta-l 
receptors. When, however, isoprenaline was compared to the beta-2 
agonist salbutamol and to the beta-l agonist prenalterol, it was 
found that beta-2 receptor stimulation was mainly responsible for 
the rise in renin. The data are best explained by presynaptic 
beta-2 receptor activatien facilitating the release of 
noradrenaline in the kidney. Noradrenaline subsequently acts on 
postsynaptic beta-l receptars to cause a rise in renin release. 
Indeed, after isoprenaline and after salbutamol there was a close 
linear correlation between the rise in noradrenaline and the rise 
in renin. 
That beta-l receptor stimulation per se had little effect on 
renin needs to be explained. It may be of importance that 
prenalterol is nat a full but rather a partial beta-l receptor 
agonist. With a high prevailing level of sympathetic nerveus 
activity in the kidney, prenalterol may cause little further 
beta-l receptor stimulation. In contrast, facilitation of 
transmitter release may have its greatest effect under these 
circumstances. 
The rise in renin after beta-2 receptor stimulation is nat 
likely to be due to a reflex increase in sympathetic tone. It has 
previously been argued that isoprenaline and salbutamol are 
likely to cause a reflex fall in sympathetic tone. Furthermore, 
while there was a close linear correlation between the rise in 
renin and the rise in noradrenaline, there was na such 
correlation with the fall in diastolic pressure. The data are 
therefore interpreted as evidence that presynaptic beta-2 
receptor stimulation increases noradrenaline release and thereby 
leads to a postsynaptic beta-l receptor mediated response, i.e. a 
rise in renin. 
Our conclusions may be summarized as fellows: 
1) Beta-2 agonists increase plasma noradrenaline, most likely 
reflecting a direct influence on neuronal release of 
noradrenaline. 
2) The beta-2 agonist-induced increase in noradrenaline is 
associated with a postsynaptic beta-l response, namely a 
rise in renin. 
3) Adrenaline, in physiological concentrations, increases 
plasma noradrenaline. This effect is also mediated by beta 
receptors. 
4) Adrenaline, in physiological concentrations, amplifies the 
postsynaptic alpha receptor mediated blood pressure response 
to standardized sympathetic stimulation~ This effect of 
adrenaline is also mediated by beta receptors. 
5) Treatment of essential hypertension with a selective beta-2 
receptor antagonist causes a fall in blood pressure. 
In view of the above conclusions there is now good evidence that 
presynaptic beta-2 receptars exist in humans and that these 
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recepters play a role in blood pressure regulation. Activatien of 
these recepters by the hormone adrenaline enhances the 
cardiovascular effect of sympathetic nerveus activity. Blockade 
of these recepters leads to a fall.in blood pressure in patients 
with essential hypertension. 
Thus the hormone adrenaline serves a hitherto unrecognized 
function. It amplifies the signal transmission in the sympathetic 
nerveus system. One may envisage the usefulness of such a 
function. Physiological studies have shown that noradrenaline, 
after its release, may act on presynaptic alpha recepters to 
serve a negative feed-back function on further noradrenaline 
release. In this way noradrenaline will increase the 'signal-to-
noise ratio', especially at low stimulation frequencies. The 
facilitating effect of adrenaline through presynaptic beta 
recepters is likely to be most effective at high stimulation 
frequencies. Both functions are in fact complementary and serve 
to increase the 'gain' of the sympathetic nerveus system. 
As a clue to the physiological implications of the 
presynaptic effect of adrenaline one may further consider the 
circumstances when adrenaline levels are highest. These 
circumstances can generally be referred to as 'stress', either 
with or without physical activity. With physical activity, 
roetabolie waste products from exercising muscles cause 
vasodilattion and a fall in vascular resistance. Blood pressure 
is maintained by a rise in cardiac output. After stopping 
muscular exercise, cardiac output falls abruptly but vascular 
resistance remains decreased for a while, leading to a temporary 
drop in blood pressure below pre-exercise level. At this stage 
plasma adrenaline levels have come down but high levels of 
adrenaline will still be present in sympathetic nerves. 
Adrenaline may be released from these nerves and act on 
presynaptic recepters to augment the vasoconstrictor response to 
sympathetic activity. In this way a precipitous drop in blood 
pressure is prevented. 
If stress is not associated with muscular exercise, there 
seems to be no need for such a mechanism. Now high levels of 
adrenaline will perhaps lead to hypertension. In this context it 
is of interest that in patients with essential hypertension 
plasma levels of both adrenaline and noradrenaline are somewhat 
higher than in normotensive controls (17-20]. A betablocker is 
therefore a logica! choice for the treatment of essential 
hypertension. 
The mechanism whereby betablockers lower blood pressure is 
unknown. A fall in cardiac output, resetting of the baroreflex, 
postsynaptic blockade of renin release, a central effect and 
presynaptic inhibiton of noradrenaline release have all been put 
forward as possible explanations. As discussed above, our finding 
that beta-2 receptor blockade contributes to the antihypertensive 
effect of betablocker therapy provides evidence for the 
importance of presynaptic beta receptors. It is conceivable that, 
in some patients, a low dose of a non-selective betablocker will 
be as effective as a high dose of a beta-l selective blocker. If 
this is the case, one might prefer a non-selective betablocker 
for those patients who experience side effects related to the 
fall in cardiac output due beta-l receptor blockade. 
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SAMENVATTING 
Diverse experimenten in vitro en enkele onderzoekingen bij dieren 
hebben aanwijzingen opgeleverd dat sympathische zenuwvezels 
beschikken over zogenaamde presynaptische beta receptoren. Het 
zou gaan om receptoren van het beta-2 type, die gelegen zijn op 
het uiteinde van de zenuwvezels. Wanneer de sympathische zenuw 
electrisch wordt gestimuleerd, wordt noradrenaline, dat in de 
uiteinden van de zenuw ligt opgeslagen, aan de omgeving 
afgegeven. Deze afgifte wordt versterkt (gefaciliteerd) door 
activatie van de presynaptische beta receptoren. Het doel van dit 
proefschrift was te onderzoeken: 1} of presynaptische beta 
receptoren bij de mens functioneren, 2} in hoeverre deze 
receptoren een rol spelen bij cardiovasculaire reacties op 
bepaalde vormen van fysieke stress, en 3} of het bloeddruk 
verlagende effect van betablockers mede door presynaptische beta 
blokkade tot stand komt. 
Effecten van beta agonisten en antagonisten op plasma 
noradrenaline 
Eerst onderzochten we het effect van diverse beta agonisten en 
antagonisten op plasma noradrenaline. Daarbij werden de 
veranderingen in noradrenaline vergeleken enerzijds met de 
stijging van de hartfrequentie, de verkorting van de 
electramechanische systole (QS2I} en de stijging van plasma 
renine (beta-1 effecten) en anderzijds met de daling van de 
diastolische bloeddruk en van plasma kalium (beta-2 effecten). 
Bij patienten met essentiele hypertensie bleek infusie van 
isoprenaline de hartfrequentei te doen stijgen met 40 slagen/min, 
terwijl het plasma noradrenaline steeg met 75%. Na 
voorbehandeling met de beta-l antagonist atenolol was de dosis-
werkingscurve voor de stijging van noradrenaline in geringe mate 
naar rechts verschoven. Na de niet selectieve beta antagonist 
propranolol werd echter, ook bij een zelfde mate van beta-l 
stimulatie, geen noradrenaline stijging gezien. Vervolgens 
vergeleken we de beta-l agonist prenalterol met de beta-2 agonist 
salbutamol in doseringen waarbij elk de hartfrequentie deed 
stijgen met 20 slagen/min. Na salbutamol steeg het plasma 
noradrenaline met 75%, maar na prenalterol veranderde het 
noradrenaline niet. Hieruit blijkt dat activatie van beta 
receptoren, behorende tot het beta-2 type, leidt tot een toename 
van de plasma noradrenaline concentratie. 
Dat infusie van isoprenaline het plasma noradrenaline 
verhoogt is later bevestigd door Goldstein e.a. [1]. Zij vonden 
bovendien dat hierbij het plasma adrenaline gelijk bleef of iets 
daalde. Een en ander past bij beta-2 receptor gemedieerde 
facilitatie van de noradrenaline afgifte uit de sympathische 
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zenuwvezels. 
Op dez~ conclusie Z~Jn drie punten van kritiek mogelijk. 
Beta-2 receptor activatie kan door vaatverwijding de bloeddruk 
verlagen, zodat wellicht via de barereflex de sympathische 
zenuwactiviteit toeneemt. Wij menen dat dit niet de verklaring is 
voor de waargenomen stijging van noradrenaline omdat naast een 
geringe bloeddruk daling, en soms zelfs een stijging, steeds een 
sterke stijging van polsdruk en hartfrequentie optrad, waarbij 
eerder een reflex afname van de sympathische activiteit zou 
worden verwacht. Recent werd door Arnold e.a. [2] aangetoond dat 
infusie van isoprenaline bij de mens leidt tot een reflex toename 
van de parasympathische activiteit. Algemeen wordt aangenomen dat 
een barereflex gemedieerde toename van parasympathische 
activiteit gepaard gaat met een afname van de sympathische 
activiteit. 
Beta receptor activatie verhoogt de concentratie van renine 
en angiotensine-II in plasma. Naast presynaptische beta-2 
receptoren zijn er ook presynaptische angiotensine-II receptoren 
beschreven, die eveneens de afgifte van transmitter noradrenaline 
bevorderen [3].De waargenomen stijging van noradrenaline zou 
wellicht via de presynaptische faciliterende angiotensine-II 
receptoren op de sympathische zenuwvezel kunnen verlopen. In onze 
experimenten was het van isoprenaline op renine echter duidelijk 
gedissocieerd van het effect op noradrenaline. Atenolol en 
propranolol antagoneerden in gelijke mate de stijging van renine. 
Atenolol had echter weinig invloed op de stijging van 
noradrenaline terwijl propranolol deze stijging volledig 
blokkeerde. 
Tenslotte zou een stijging van noradrenaline ook nog door een 
afname van de klaring kunnen worden veroorzaakt. Van beta 
stimulatie is echter bekend dat dit de klaring van catecholamines 
juist verhoogt [4]. Op grond van onze eigen bevindingen en 
genoemde gegevens uit de literatuur mag daarom worden 
geconcludeerd dat beta-2 receptor activatie bij onze patienten 
rechtstreeks heeft geleid tot een toename van de noradrenaline 
afgifte door sympathische zenuwvezels, hetgeen een sterke 
aanwijzing is voor het functioneren van presynaptische beta-2 
receptoren. 
Effecten van adrenaline op plasma noradrenaline en op de 
cardiovasculaire respons 
De hierboven besproken farmacologische studies werden aangevuld 
met meer fysiologische studies, waarbij de invloed werd 
bestudeerd van adrenaline op het effect dat sympathische zenuw 
stimulatie in het eindorgaan teweegbrengt. Bij patienten met 
essentiele hypertensie en bij normotensieve vrijwilligers werden 
de zgn. 'cold presser-test' en een isometrische inspanningstest 
uitgevoerd, eerst tijdens infusie van fysiologisch zout, daarna 
tijdens adrenaline 30 ngjmin per kg lichaamsgewicht. Door 
adrenaline infusie steeeg het plasma adrenaline tot hoge 
fysiologische waarden, gemiddeld tot 800 pgjml. Het plasma 
noradrenaline steeg met 30%. De hartfrequentie steeg 8 slagenjmin 
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en de diastolische bloeddruk daalde 10 mmHg. De bloeddrukstijging 
op beide stimulatietesten, die door alpha receptoren wordt 
gemedieerd, was tijdens adrenaline infusie significant 
toegenomen. De verandering in de hartfrequentie, die aan afname 
van parasympathische activiteit wordt toegeschreven, werd niet 
door adrenaline beinvloed. Tijdens de adrenaline infusie werd aan 
een aantal patienten propranolol, 0,5 mg intraveneus, toegediend. 
Propranolol deed de hartfrequentie en bloeddruk juist tot de 
uitgangswaarden terugkeren. (Dat de hartfrequentie niet verder 
daalde suggereert dat propranolol in deze dosering selectief de 
beta-2 receptoren blokkeerde.) Na propranolol daalde het plasma 
noradrenaline tot beneden de controlewaarde. Tevens bleek de 
versterkende invloed van adrenaline op de bloeddruk-respons 
volledig geblokkeerd. Uit deze experimenten blijkt dat 
adrenaline, in een fysiologische concentratie, via beta receptor 
activatie leidt tot een stijging van het plasma noradrenaline en 
tot een versterking van de alpha receptor gemedieerde response op 
sympathische stimulatie. 
Recent werd een vergelijkbare bevinding gedaan door Floras 
e.a. [5]. Als stimulus werd door deze onderzoekers gebruik 
gemaakt van een negatieve druk aangelegd om de benen. Dit leidde 
via een sympathische respons tot vaatvernauwing, die aan de 
onderarm d.m.v. plethysmografie werd gemeten. Wanneer 
isoprenaline of adrenaline in de arteria brachialis werd 
toegediend, in zo lage doseringen dat hiervan geen systemisch 
effect werd gezien, bleek deze respons significant toegenomen. 
Een verhoogde receptor gevoeligheid kon worden uitgesloten, omdat 
de vaatvernauwing na infunderen van noradrenaline niet was 
toegenomen. Het effect van adrenaline hield aan tot minstens 30 
min na beeindiging van de infusie. Binnen onze eigen groep 
onderzochten Blankenstijn e.a. [6] het effect van een 6 uur 
durende intraveneuze infusie van adrenaline 15 ngjmin per kg 
lichaamsgewicht, waarbij plasma spiegels werden bereikt van 250 
pgjml. Het effect van adrenaline werd vergeleken met dat van 
noradrenaline en met dat van fysiologisch zout. Ook in deze 
relatief lage dosering bleek adrenaline de bloeddruk respons op 
de cold presser test en op isometrische inspanning te versterken. 
Na het beeindigen van de infusie bleef de bloeddruk gedurende 
minstens 18 uur verhoogd ten opzichte van de controle waarden. 
Een en ander maakt waarschijnlijk dat presynaptische facilitatie 
van de noradrenaline afgifte onder invloed van adrenaline een 
fysiologische rol kan spelen bij het handhaven of verhogen van de 
bloeddruk, en dat deze rol niet beperkt blijft tot de tijd waarin 
de plasma adrenaline spiegel verhoogd is. Dit laatste pleit voor 
de mogelijkheid dat adrenaline na neuronale opname weer wordt 
afgegeven om dan opnieuw presynaptische receptoren te activeren 
[ 7] • 
Effect van een beta-2 selectieve antagonist op de bloeddruk 
Als het zo is dat adrenaline via beta-2 receptoren de bloeddruk 
kan verhogen, is ook te verwachten dat beta-2 blokkade de 
bloeddruk kan verlagen. Daarom werd het effect op de bloeddruk 
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bestudeerd van een beta-2 selectieve blocker, ICI 118551. In een 
dubbelblinde placebo-gecontroleerde crossover trial werd het 
effect van een week behandeling met ICI 118551, 3 dd 50 mg, 
vergeleken met placebo en met een week propranolol, 3 dd 80 mg. 
Door metingen van bloeddruk, hartfrequentie, systolische 
tijdsintervallen, plasma kalium, noradrenaline en renine tijdens 
infusie van isoprenaline werd vastgesteld dat de gebruikte dosis 
van ICI 118551 inderdaad beta-2 selectief was. Voor zowel ICI 
118551 als voor propranolol gold dat, 2 uur na inname van de 
eerste tablet, de hartfrequentie was gedaald terwijl de bloeddruk 
niet was veranderd. Na een week voortgezette behandeling, echter, 
bleken systolische en diastolische bloeddruk, indirect en intra-
arterieel gemeten, zowel na beta-2 selectieve blokkade als na 
propranolol te zijn verlaagd. Verder was na beide betablockers de 
hartfrequentie en de plasma renine concentratie verlaagd. Met 
andere woorden, bij vergelijking van de effecten van beta-2 
selectieve blokkade met niet-selectieve beta blokkade bleken de 
patronen van de verandering van hartfrequentie, renine en 
bloeddruk, ook qua beloop in de tijd, sterk overeen te komen. De 
gegevens zijn dan ook goed verenigbaar met de hypothese dat 
presynaptische beta-2 blokkade, door inhibitie van de 
noradrenaline afgifte, de bloeddruk verlaagt. Wel moet worden 
opgemerkt dat na beta-2 selectieve blokkade de bloeddrukdaling 
minder leek te zijn dan na propranolol. Het is daarom aannemelijk 
dat beta-l blokkade bijdraagt aan de bloeddruk verlagende werking 
van betablockers. 
Als argument tegen de bijdrage van presynaptische beta 
blokkade aan de bloeddruk verlagende werking van betablockers is 
aangevoerd dat inhibitie van de noradrenaline afgifte tot uiting 
had moeten komen in een daling van de plasma spiegel van 
noradrenaline. Wij vonden na beta-2 blokkade een niet 
significante daling van de noradrenaline spiegel en na 
propranolol een stijging. Hierbij moet worden opgemerkt dat na 
beta blokkade de noradrenaline klaring afneemt [4,8,9]. Verder 
zijn er aanwijzingen dat de daling van het hartminuutvolume na 
beta blokkade een reflex toename van de sympathische activiteit 
kan veroorzaken [10]. Beide mechanismen zullen een stijging van 
het plasma noradrenalne tot gevolg hebben. In een aantal studies 
is gevonden dat de noradrenaline afgifte of uitscheiding in de 
urine na beta blokkade daalt, vooral bij diegenen bij wie ook de 
bloeddruk daalt [11-14]. Ook blijkt de bloeddrukdaling na beta 
blokkade door een daling van de vaatweerstand verklaard te moeten 
worden [10]. Deze observaties passen juist goed bij het 
mechanisme van presynaptische beta blokkade. 
Effect van beta agonisten en antagonisten op plasma renine 
Voor wat betreft het type betareceptor dat betrokken is bij de 
stimulatie van renine afgifte zijn de gegevens in de literatuur 
niet eensluidend. Dit was de aanleiding om een nadere analyse te 
maken van de renine response op de verschillende door ons 
gebruikte betareceptor agonisten en antagonisten. De verandering 
in het renine werd vergeleken met de gelijktijdige verkorting van 
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de electramechanische systole (QS2I) en daling van de 
diastolische bloeddruk, parameters van respectievelijk beta-l en 
beta-2 stimulatie. Bij eenzelfde diastolische drukdaling 
veroorzaakten isoprenaline en de beta-2 agonist salbutamol een 
gelijke stijging van het plasma renine. Bij eenzelfde verkorting 
van de QS2I veroorzaakte de beta-l agonist prenalterol een 
geringere stijging van renine dan isoprenaline. Uit bestudering 
van de effecten van isoprenaline infusie zowel voor en na 
propranolol als voor en na atenolol bleek dat beide betablockers 
de renine respons curve in dezelfde mate naar rechts verschoven 
als de curve van de QS2I-verandering. Uit bestudering van de 
effecten van isoprenaline voor en na de beta-2 antagonist ICI 
118551 en voor en na propranolol bleek dat beide betablockers de 
diastolische drukdaling geheel teniet deden en dat propranolol 
een aanzienlijke verschuiving van de renine respons curve 
bewerkstelligde, terwijl ICI 118551 hierop weinig invloed had. 
Met andere woorden, zowel beta-l als beta-2 stimulatie kunnen het 
plasma renine doen stijgen. Tevens kon worden aangetoond dat de 
renine response moest verlopen via beta-l receptor stimulatie. Na 
toediening van isoprenaline of van salbutamol was er een 
positieve lineaire correlatie tussen de stijging van renine en 
die van noradrenaline, maar niet tussen de stijging van 
noradrenaline en de diastolische drukdaling. In het licht van wat 
hiervoor werd besproken kunnen de gegevens het best worden 
geïnterpreteerd als een sterke aanwijzing dat presynaptische 
beta-2 receptor stimulatie de noradrenaline afgifte verhoogt en 
daardoor een postsynaptische beta-l receptor gemedieerde 
response, in casu een stijging van het renine, veroorzaakt. 
CONCLUSIES 
Onze conclusies kunnen als volgt worden samengevat. 
1) Beta-2 agonisten verhogen het plasma noradrenaline, 
waarschijnlijk door een rechtstreekse invloed op de 
neuronale afgifte van noradrenaline. 
2) De door beta-2 agonisten geïnduceerde stijging van 
noradrenaline gaat gepaard met een postsynaptische 
beta-l respons, namelijk een stijging van het plasma 
renine. 
3) Adrenaline, in fysiologische concentraties, verhoogt 
het plasma noradrenaline. Dit effect komt ook tot stand 
door betareceptor stimulatie. 
4) Adrenaline, in fysiologische concentraties, leidt tot 
een versterking van een postsynaptische alpha response, 
namelijk de bloeddrukstijging tijdens bepaalde 
gestandaardiseerde vormen van fysieke stress. Dit 
effect van adrenaline komt eveneens tot stand door beta 
receptor stimulatie. 
5) Behandeling van hypertensie met een beta-2 selectieve 
antagonist veroorzaakt een daling van de bloeddruk. 
Deze conclusies zijn sterke argumenten dat de mens beschikt over 
presynaptische beta-2 receptoren, die een rol spelen bij de 
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regulatie van de bloeddruk. Activatie van deze beta-2 receptoren 
door het hormoon adrenaline versterkt het effect van sympathische 
zenuwstimulatie door toegeneeroen afgifte van de neurotransmitter 
noradrenaline. Blokkade van beta-2 receptoren leidt tot een 
daling van de bloeddruk bij patienten met essentiele hypertensie. 
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